YEDİTEPE UNIVERSITY

FACULTY OF MEDICINE

PHASE III

ACADEMIC PROGRAM BOOK

2020 - 2021

Student's
Name : .....
Number : .....

YEDİTEPE UNIVERSITY

FACULTY OF MEDICINE

PHASE III

CONTENT

Page

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE

AIM OF MEDICAL EDUCATION PROGRAM

*"Consensus Commission Report" based on draft compiled at "*Workshop for Revision of Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of Medicine*"

AIM

The aim of medical education program ***is to graduate physicians*** who

- **are aware of** the local and global health issues
- **have acquired competence** in knowledge, skills and attitudes to manage and provide primary health care service
- **know**, **apply** and **care** for ethical principles of the medical profession
- **keep up with** current knowledge at national and international level
- **are capable of** systematical thinking
- **are** investigative and questioning
- continually **renovate** and **improve** themselves
- **are capable of** teamwork
- **use** technology competently in medicine and related areas
- **have** effective communication skills
- **have** community leadership qualifications

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE

PROGRAM OUTCOMES OF MEDICAL EDUCATION PROGRAM

Abbreviations: PO: Program Outcomes, POD: Program Outcomes Domain, PODG: Program Outcomes Domain Group

PODG.1. Basic Professional Competencies

POD.1.1. Clinical Competencies

PO.1.1.1. ***values*** preventive health services, ***offers*** primary prevention (i.e. prevention of diseases for the protection of health), secondary prevention (i.e. early diagnosis and treatment) tertiary prevention (i.e. rehabilitation) and quaternary prevention (i.e. prevention of excessive and unnecessary diagnosis and treatment) services, ***provides*** consultancy on these issues.
PO.1.1.2. ***employs*** a patient-centered approach in patient management.
PO.1.1.3. ***recognizes*** most frequently occurring or significant clinical complaints, symptoms, signs, findings and their emergence mechanisms in clinical conditions.
PO.1.1.4. ***takes*** medical history from the applicant himself/herself or from the individual's companions.
PO.1.1.5. ***does*** general and focused physical and mental examination.
PO.1.1.6. ***interprets*** findings in medical history, physical and mental examination.
PO.1.1.7. ***employs*** diagnostic procedures that are used frequently at the primary health care level.
PO.1.1.8. ***selects*** tests that have evidence-based high efficacy at the primary health care level and ***interprets*** results.
PO.1.1.9. ***makes*** clinical decisions using evidence-based systematic data in health care service.
PO.1.1.10. ***performs*** medical interventional procedures that are used frequently at the primary health care level.
PO.1.1.11. ***manages*** healthy individuals and patients in the context of health care services.
PO.1.1.12. ***keeps*** medical records in health care provision and ***uses*** information systems to that aim.

POD.1.2. Competencies related to Communication

PO.1.2.1. throughout his/her career, ***communicates*** effectively with health care beneficiaries, co-workers, accompanying persons, visitors, patient's relatives, care givers, colleagues, other individuals, organizations and institutions.
PO.1.2.2. ***collaborates*** as a team member with related organizations and institutions, with other professionals and health care workers, on issues related to health.
PO.1.2.3. ***recognizes*** the protection and privacy policy for health care beneficiaries, co-workers, accompanying persons and visitors.
PO.1.2.4. ***communicates*** with all stakeholders taking into consideration the socio-cultural diversity.

POD.1.3. Competencies Related to Leadership and Management

PO.1.3.1. ***manages*** and ***leads*** within the health care team in primary health care organization.
PO.1.3.2. ***recognizes*** the principles of health management and health sector economy, models of organization and financing of health care services.
PO.1.3.3. ***recognizes*** the resources in the health care service, the principles for cost-effective use.

POD.1.4. Competencies related to Health Advocacy

PO.1.4.1. ***recognizes*** the health status of the individual and the community and the factors affecting the health, ***implements*** the necessary measures to prevent effects of these factors on the health.
PO.1.4.2. ***recognizes*** and ***manages*** the health determinants including conditions that prevent access to health care.

POD.1.5. Competencies related to Research

PO.1.5.1. ***develops***, ***prepares*** and ***presents*** research projects

POD.1.6. Competencies related to Health Education and Counseling

PO.1.6.1. ***provides*** consultancy services and ***organizes*** health education for the community to sustain and promote the health of individual and community**.**

PODG.2. Professional Values and Perspectives

POD.2.1. Competencies related to Law and Legal Regulations

PO.2.1.1. ***performs*** medical practices in accordance with the legal framework which regulates the primary health care service.

POD.2.2. Competencies Related to Ethical Aspects of Medicine

PO.2.2.1. ***recognizes*** basic ethical principles completely, and ***distinguishes*** ethical and legal problems.

PO.2.2.2. ***pays importance to*** the rights of patient, patient's relatives and physicians, and ***provides*** services in this context.

POD.2.3. Competencies Related to Social and Behavioral Sciences

PO.2.3.1. ***relates*** historical, anthropological and philosophical evolution of medicine, with the current medical practice.

PO.2.3.2. ***recognizes*** the individual's behavior and attitudes and factors that determine the social dynamics of the community.

POD.2.4. Competencies Related to Social Awareness and Participation

PO.2.4.1. ***leads*** community with sense of responsibility, behavior and attitudes in consideration of individual behaviors and social dynamics of the community, and if there is a necessity, ***develops*** projects directed towards health care services.

POD.2.5. Competencies Related to Professional Attitudes and Behaviors

PO.2.5.1. ***displays*** a patient-centered and holistic (biopsychosocial) approach to patients and their problems.

PO.2.5.2. ***respects*** patients, colleagues and all stakeholders in health care delivery.

PO.2.5.3. ***displays*** the proper behavior in case of disadvantaged groups and situations in the community.

PO.2.5.4. ***takes*** responsibility for the development of patient safety and healthcare quality.

PO.2.5.6. ***evaluates*** own performance as open to criticism, ***realizes*** the qualifications and limitations.

PODG.3. Personal Development and Values

POD.3.1.Competencies Related to Lifelong Learning

PO.3.1.1. ***embraces*** the importance of lifelong self-learning and ***implements***.

PO.3.1.2. ***embraces*** the importance of updating knowledge and skills; ***searches*** current advancements and ***improves*** own knowledge and skills.

PO.3.1.3. ***uses*** English language at least at a level adequate to follow the international literature and to establish communication related to the profession.

POD.3.2. Competencies Related to Career Management

PO.3.2.1. ***recognizes*** and ***investigates*** postgraduate work domains and job opportunities.

PO.3.2.2. ***recognizes*** the application requirements to postgraduate work/job domains, and ***distinguishes*** and ***plans*** any requirement for further training and work experience.

PO.3.2.3. ***prepares*** a resume, and ***recognizes*** job interview methods.

POD.3.3. Competencies Related to Protection and Development of Own Physical and Mental Health

PO.3.3.1. ***implements*** the rules of healthy living.

PO.3.3.2. ***displays*** appropriate behavior specific to work under stressful conditions.

PO.3.3.3. ***uses*** self-motivation factors.

YıEDİTEPEUNIVERSITY IFACULTY OF MEDICINE

2020-2021 A&#xFFFD;DEMIC YiEAR ANNOUNCEMENT (PHASE11-11-111)

Dear Ali,

in a statement of The Higher Education Council of Ttırkey (YÖK) related a new normalizatıion process indudes the expressions that: "Turkish Universitıies need ta schedule their own onlıine education pmoess far relevant programs ta be abıle ta give its theoretical lecttı&#xFFFD;es and support its practicalı trainings oonsidering the regional and llocal dynamics of COVI0-19 pandemic and the number ofstıudent and infrastructur:e facilities of the relevant formal pmgıram. Also, ıit has been deciided that in the faoe-to-face programs, up ta 40 percent of courses can be lectured as online regardless of COVID-19 pandemic process.

liowever, at that point far 2020-2021 academic year as Faculty of Medicine, we have ta&#xFFFD;en some decisi·ons listed be·low in consequence of our experiences, resolutions ofYedit,epe Universfty Senate, disoussions withiınotır edıucatioınal commissions and your ıeedbacks aınd reqıuests.

- Preclinical students (Phase 1-11-111) ar,e going ta get integrated education (both practical and theoretica,l lecturesl as usual. The current academic program will be protected.
- The lecture commiss•ions and the other code of courses' (ICP, laboratory and practical skillls, anatomical drawıing, prob&#xFFFD;lem-based learning se.ssions aınd rree elective courses) theoretical parts wilıl be given synchronotıs and online.
- The lectures' v,ideo &#xFFFD;ecording w,ill be hold. in this way, students have a chanoe and opportunity ta watch these videos as asynchronous in case of missing the lecture.
- it ıis on our agenda that in the spring semester the theoretical exams will be conducted face ta face considering the physical and academic infırastrıucture, the other facillities and taken tihe neoessary measures of our University. in tile talil semester theor etical exams will be synchronous and online. The examinatıion ıru'les wiilıl be declared at a later time.
- The pract,ical tıraıining alsa will be given as online and synchronous as possibillities allow. lf some practices postpone ta spring semest,er, it will be planned to given face ta faoe by divided ıinto group,s.
- 2020-2021 academic year program far precliınical students is preparing and go.ing ta be announced on otır Faetılty web site.

Asa rnnsequence, the whole lectur,es wiilıl be given as onlıine and synchronous / asynchronous in 2020-2021academic year fail semester. We are expecting and planınıing tihe realization of face-to-faoe aınd mostly pr:actical training far spring semest,er, but tak,ing into ,consideration that the pllanning face-to-face education might be transformed ıinto online mode.ı in case of farce majeure related with the progress of COV|ID-19 pandemic.

New academic programs is going ta be declared as soon as possible.

We wish yatı alll stıccess and joy far thıis new academıic year.

Prof. Dr. Sina Ercan
Dean

COORDINATION COMMITTEES

(TEACHING YEAR 2020 – 2021)

PHASE-III COORDINATION COMMITTEE

Hale ARIK TAŞYIKAN, MD, Assist. Prof. (Coordinator)
Hasan AYDIN, MD, Prof. (Co-coordinator)
Erdem SÖZTUTAR, MD, Assist. Prof. (Co-coordinator)
Emine Nur ÖZDAMAR, MD, Assist. Prof. (Co-coordinator)
Arzu YALÇIN, Assist. Prof. (Co-coordinator)

ICP-III COORDINATION COMMITTEE

Özlem TANRIÖVER, MD, Prof. (Coordinator)
Ayşe Arzu AKALIN, MD, Assist. Prof. (Co-coordinator)

ELECTIVE COURSES COORDINATION COMMITTEE

Ayşe Arzu AKALIN, MD, Assist. Prof. (Coordinator)
Seda GÜLEÇ, PhD. Assoc. Prof. (Co-coordinator)

DESCRIPTION and CONTENT

Physiopathological process and pathological process.

Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System, Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry, Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.

Emergency Medicine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics, Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology, Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology, Gastroenterohepathology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophtalmology, Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology, Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology, Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology, Medical Education.

AIMS and LEARNING OBJECTIVES of PHASE III

AIMS

In evidence based manner:

1. ***to remind*** anatomy, histology and physiology of body systems,
2. ***to convey*** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
3.1. ***to convey*** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
3.2. ***to convey*** knowledge on epidemiology,
3.3. ***to convey*** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
3.4. ***to convey*** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health care service,
4. ***to convey*** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. ***to convey*** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. ***to convey*** knowledge on biostatistical analysis,
7. ***to convey*** basic legal and ethical principles that should be followed in practice of medical profession,
8. ***to equip with*** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

LEARNING OBJECTIVES

At the end of this phase, student should be able to:

1.0 ***recall*** anatomy, histology and physiology of body systems.
2.0 ***list*** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
3.0 ***explain*** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
4.0 at cellular or tissue level,
4.1. ***recognize*** morphological characteristics,
4.2. ***show*** basic pathological changes that occur in clinical conditions.
5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
5.1. ***explain*** mechanisms of destruction at molecule, cell, tisssue, organ, system, multi-system and organismal level,
5.2. ***describe*** structural and functional changes caused,
5.3. ***list*** clinical courses in time.
6.0. ***explain*** mechanisms of emergence for frequently encountered;
6.1. clinical complaints,
6.2. symptoms,
6.3. signs,
6.4. laboratory and imaging findings
of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
7.0. at multi-system level or related to a body system,
• for healthy conditions in an individual or community with a request, or
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
• health care processes,
• acquisition of subjective or objective data, information and knowledge required for clinical decision making,
• clinical decision making process,
• clinical decisions and

• clinical practices
which are required for management at primary health care service level.
7.1. practice of history taking and physical examination (*cardiovascular, pulmonary, gastrointestinal, gynecological, breast, neonatal, prepubertal/pubertal, neurological/neuropsychiatric, musculoskeletal*)
7.2. evaluation of emergency case (*sepsis and septic shock, dyspnea, acute abdominal pain, urological emergencies, neurological emergencies, trauma*)
7.3. approach to healthy individual or patient (*fever, cardiovascular disease, chest pain, cough and hemoptysis, dyspnea, anemia, lymphadenopathy, diarrhea, pregnancy, urinary tract infection, neurological symptoms, headache, depression, dementia, musculoskeletal dysfunction*)
7.4. laboratory and imaging tests/examinations
7.4.1. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests:
i. *(venous blood collection*)
ii. *(thyroid function tests, diabetes tests)*
2. medical microbiology tests:
i. *(urine sample collection, throat swab specimen, sputum sample collection, urethral-vaginal-cervical discharge/swab specimen, fecal specimen collection, wound sample collection, blood collection for culture*)
ii. *(urine strip/dipstick test, urine culture, rapid screening (antigen/antibody) tests, throat culture, sputum culture, urethral-vaginal-cervical discharge culture, fecal culture, wound culture, blood culture)*
3. medical pathology tests:
i. *Pap smear collection*
ii. *Pap smear*
4. other laboratory tests:
i. *(peripheral/venous blood collection for hematology tests, blood sample collection for therapeutic drug monitoring)*
ii. *(pulmonary function tests, hematology tests for anemia, monitarization of drug therapy)*

5. radiological examinations: *(radiological examinations in gynecology, breast imaging, uroradiology, conventional neuroradiological examinations, spinal neuroradiology, cranial CT, cranial MRI, radiological imaging of musculoskeletal system, radiological examinations in benign ve malign tumors of bones)*
6. nuclear medicine examinations: *(nuclear medicine tests in infectious diseases, radionuclide ventriculography, myocardial scintigraphy, cardiac PET, ventilation/perfusion scintigraphyi, PET in lung cancer, nuclear medicine tests in hematology, scintigraphy of liver/spleen, PET in gastrointestinal system tumors, radioisotope imaging of thyroid and parathyroid, renal scintigrahy (GFR, ERPF, Renogram), brain perfusion scintigraphy, brain PET, bone scintigraphy)*

7.4.3. point of care testing
a. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests: *(diabetes tests, cardiac markers, coagulation tests, blood gases).*
2. medical microbiology tests: *(urine strip/dipstick test, rapid screening (antigen/antibody tests)*
3. other laboratory testsi: *(hematology-peripheral blood smear examination, hematology-complete blood count)*

7.5. making preliminary diagnosis or definitive diagnosis decision
7.6. making non-intervention or intervention decision
7.7. practicing non-intervention or intervention
7.8. referral/transport of healthy individual or patient

INSTRUCTIONAL DESIGN of PRECLINICAL YEARS

In Phase I, II and III, the formation of committees is based on a thematic structure. This structure corresponds to organizational levels of human body such that macromolecule, organelle, cell, tissue, organ systems and finally introduction to pathogenesis.

- Phase I: Normal structure and function of human body at molecular, cellular, tissue and organ level.
- Phase II: Normal structure and function of human body at system and multi-system level, and introduction to pathogenesis.
- Phase III: Physiopathological and pathological processes in human body.

Besides this thematic structure, there is a continuous clinical skills education in Phase I, II and III, as “Introduction to Clinical Practice -I, -II and -III” courses.

Therefore, the core medical courses are;

- Phase I: MED 104 Basic Medical Sciences I, MED 102 Introduction to Clinical Practice I, MED 103 Anatomical Drawing,
- Phase II: MED 201 Basic Medical Sciences II, MED 202 Introduction to Clinical Practice II,
- Phase III: MED 302 Introduction to Clinical Sciences, MED 303 Introduction to Clinical Practice III.

The learning objectives of the phase include learning objectives of core courses. The learning objectives of committees include learning objectives of core courses’ components for the committee.

INTRODUCTION to CLINICAL SCIENCES (MED 302)

AIMS

In evidence based manner:

1. ***to remind*** anatomy, histology and physiology of body systems,
2. ***to convey*** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
3.1. ***to convey*** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
3.2. ***to convey*** knowledge on epidemiology,
3.3. ***to convey*** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
3.4. ***to convey*** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health care service,
4. ***to convey*** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. ***to convey*** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. ***to convey*** knowledge on biostatistical analysis,
7. ***to convey*** basic legal and ethical principles that should be followed in practice of medical profession,

LEARNING OBJECTIVES

At the end of this phase, student should be able to:

1.0 ***recall*** anatomy, histology and physiology of body systems.
2.0 ***list*** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
3.0 ***explain*** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
4.0 at cellular or tissue level,
4.1. ***recognize*** morphological characteristics,
4.2. ***show*** basic pathological changes that occur in clinical conditions.
5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
5.1. ***explain*** mechanisms of destruction at molecule, cell, tisssue, organ, system, multi-system and organismal level,
5.2. ***describe*** structural and functional changes caused,
5.3. ***list*** clinical courses in time.
6.0. ***explain*** mechanisms of emergence for frequently encountered;
6.1. clinical complaints,
6.2. symptoms,
6.3. signs,
6.4. laboratory and imaging findings
of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
7.0. at multi-system level or related to a body system,
• for healthy conditions in an individual or community with a request, or
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
• health care processes,
• acquisition of subjective or objective data, information and knowledge required for clinical decision making,
• clinical decision making process,
• clinical decisions and
• clinical practices
which are required for management at primary health care service level.

7.1. evaluation of emergency case (*sepsis and septic shock, dyspnea, acute abdominal pain, urological emergencies, neurological emergencies, trauma*)
7.2. approach to healthy individual or patient (*fever, cardiovascular disease, chest pain, cough and hemoptysis, dyspnea, anemia, lymphadenopathy, diarrhea, pregnancy, urinary tract infection, neurological symptoms, headache, depression, dementia, musculoskeletal dysfunction*)
7.3. laboratory and imaging tests/examinations
7.3.1. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests:
i. *(venous blood collection*)
ii. *(thyroid function tests, diabetes tests)*
2. medical microbiology tests:
i. *(urine sample collection, throat swab specimen, sputum sample collection, urethral-vaginal-cervical discharge/swab specimen, fecal specimen collection, wound sample collection-,blood collection for culture*)
ii. *(urine strip/dipstick test, urine culture, rapid screening (antigen/antibody) tests, throat culture, sputum culture, urethral-vaginal-cervical discharge culture, fecal culture, wound culture, blood culture)*
3. medical pathology tests:
i. *(Pap smear collection)*
ii. *(Pap smear)*

4. other laboratory tests:
i. *(peripheral/venous blood collection for hematology tests, blood sample collection for therapeutic drug monitoring)*
ii. *(pulmonary function tests, hematology tests for anemia, monitarization of drug therapy)*

7.3.2. imaging tests/examinations based on disciplines/subdisciplines:
1. radiological examinations: *(radiological examinations in gynecology, breast imaging, uroradiology, conventional neuroradiological examinations, spinal neuroradiology, cranial CT, cranial MRI, radiological imaging of musculoskeletal system, radiological examinations in benign ve malign tumors of bones)*
2. nuclear medicine examinations: *(nuclear medicine tests in infectious diseases, radionuclide ventriculography, myocardial scintigraphy, cardiac PET, ventilation/perfusion scintigraphyi, PET in lung cancer, nuclear medicine tests in hematology, scintigraphy of liver/spleen, PET in gastrointestinal system tumors, radioisotope imaging of thyroid and parathyroid, renal scintigrahy (GFR, ERPF, Renogram), brain perfusion scintigraphy, brain PET, bone scintigraphy)*

7.3.3. point of care testing
a. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests: *(diabetes tests, cardiac markers-, coagulation tests-, blood gases).*
2. medical microbiology tests: *(urine strip/dipstick test, rapid screening (antigen/antibody tests)*
3. other laboratory testsi: *(hematology-peripheral blood smear examination, hematology-complete blood count)*

7.5. making preliminary diagnosis or definitive diagnosis decision
7.6. making non-intervention or intervention decision
7.7. referral/transport of healthy individual or patient

INTRODUCTION to CLINICAL PRACTICE- I-II-III (MED 102, 202, 303)

Due to the pandemic conditions ICP Program will be held online during the Fall Semester. Any changes in the program will be announced later.

AIM of ICP PROGRAM

This course aims to equip the students with basic medical skills such as history taking regarding to systems and in general, physical and mental examination in simulated environments in pre-clinical period and to give the students opportunity to develop skills by applying non –invasive or invasive procedures on the mannequins before encountering with real patients. The students improve the gained skills by observing real encounters in the clinical settings during 2nd and 3rd year.

Description

ICP is a three year longitudinal course that aims to introduce students to the concepts and main elements of medical practice. It will also be an introduction to the medical profession as a whole and will provide a foundation for clinical practice. The course provides knowledge, cognitive and motor skills and experience in fundamental processes and aspects of medical practice. It involves the application of scientific theory, quality assurance and evidence-based best practice protocols.

Credit Facility:

This course has 5 ECTS credits for the first and third year students while it is 4 ECTS for the second year students and all of the students are required to pass this course in order to pass the year.

Content of the ICP I-II-III

First year medical students gain knowledge on First Aid approaches, develop skills in Basic Life Support, Patient/Casualty Transportation and Bandaging Techniques regarding to First Aid. They also acquire basic knowledge on communication and experience patient-doctor encounter with simulated patients (SP's).

The second years ICP Program consist of modules like handwashing, wearing sterile gloves, assessing vital signs, nasogastric intubation, bladder catheterization, intramuscular, subcutaneous, intradermal and intravenous injections as well as iv. catheterization.

In the third year medical students practice with SP's clinical skills like history taking and physical examination focused on body systems and in general and also mental examination. They also gain clinical skills such as suturing techniques and Advanced Cardiac Life Support.

Clinical Skills Laboratory

The Clinical Skills Laboratory is designed for teaching and assessing students at undergraduate level (during the preclinical period from first-year to third year). The lab provides learners with the ideal setting to practice the clinical skills of history taking, physical examination, communication, and gives opportunities to practice invasive and non invasive procedural skills on mannequins.

Each exam room is equipped with video cameras and microphones to record the encounter. An observation area at the center of the lab allows faculty and students to observe the encounters live or view digital recordings for subsequent analysis.

Simulated Patients (SPs)

The simulated patient encounters provide transition of students from the classroom to standardized patient contact in safe environments.

Encounters with specially trained individuals, known as simulated patients (SPs), simulate specific cases in outpatient and emergency settings. The pool of SPs consist of adults, from various backgrounds.

Clinical cases are created through research and extensive training of the patients portraying these roles.

Assessment: The Assessment procedure of ICP is given in Assessment Table in this booklet.

Rules for Attendance of the Students: Students are grouped into 4 and group lists are announced in the announcement board at the beginning of the year. Any changes to practical groups on a week by week basis, will only be considered in exceptional situations such as a medical one. Any changes must be requested by a petition along with relevant documentation to the course coordinator. Any change in sessions will only be accepted interchangeably with another student in another group based on availability of work spaces and course coordinator's discretion (based on evidence provided).
Students are required to follow the rules of professional ethics in the laboratory at any time.

When an OSCE is conducted both students and faculty members complete a written evaluation of the event for the improvement of the course and OSCE.

INTRODUCTION to CLINICAL PRACTICE III (ICP-III) (MED 303)

AIM

The aim of ICP III Program is to equip Phase III students with basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

LEARNING OBJECTIVES

At the end of this phase, student should be able to:

KNOWLEDGE

1. **define** the basic terminology used in general and organ system spesific physical examination.
2. **describe** the steps of history taking and physical examination (cardiovascular, pulmonary, ear/nose/throat, gastrointestinal, gynecological, obstetric, breast, neonatal, prepubertal / pubertal, neurological / psychiatric, musculoskeletal)**.**
3. **describe** suture materials and choose the appropriate material**.**

SKILLS

1. **apply** Advance Cardiac Life Support on an adult model in accordance with the skill procedure**.**
2. **perform** sutures in accordance with the skill procedure**.**
3. **perform** history taking and physical examination (cardiovascular, pulmonary, ear/nose/throat, gastrointestinal, gynecological, obstetric, breast, neonatal, prepubertal / pubertal, neurological / psychiatric, musculoskeletal) on simulated patients or mannequins in accordance with the skill procedure.
4. **perform** intramuscular, intradermal and subcutaneous injection as well as intravenous cannulation applications in an adult model in accordance with the skill procedure**.**
5. **describe** the process to be carried out to the patient before any intervention**.**

ATTITUDE

1. **value** the importance of informed consent
2. **pay** attention to patient privacy
3. **value** the importance of not exceeding the limits of his/her own competency level.

SCIENTIFIC RESEARCH and PROJECT COURSE - III

AIM

The aim of scientific research and project course - III (SRPC – III) is to equip third year medical students with knowledge and skills of writing a scientific project proposal, and furthermore to equip with basic knowledge on scientific career and with skills of preparing CV and cover letter for scientific career.

ASSESSMENT PROCEDURE:

For the assessments of the medical students for the SRPC-III, it is calculated out of 100 points; 50% will be graded at the end of the first semester on CV and cover letter preparation assessment and 50% will be graded via scientific project proposal at the end of the second semester.

CV and cover letter assessment should be loaded to Moodle program **before 15 January 2020 Friday.**

The constraints of the scientific project proposal assignment will be discussed in Small Group Study hours, and during the year small group discussion hours on the program will be used to prepare the proposal. The project proposal should be loaded to Moodle program **before 28 May 2020 Friday.**

Scientific Projects course has 2% contribution to Term Score (TS).

Please note that it is mandatory to attend to SRPC lecture hours in the program. There will be no acceptance of assignments after the prescheduled dates.

FREE ELECTIVE COURSES

Elective courses aim to add complementary educational experiences to the medical school curriculum in order to improve comprehension of biopsychosocial approach of medical students, besides offering an opportunity to extend knowledge of interest in specific domains.
The following courses (2 ECTS credits each) will be offered in Spring semester. Each student has to choose one of these elective courses. The selection and enrollment procedure will be announced by the phase coordinator.

Code	Subject		
MED 615	**Innovation Management**		
Goals	The aim of this course is to convey to the students knowledge on innovative approaches for visionary life, describe the philosophy of futurism.		
Content	Strategies for futurism and applied case studies for personal innovation.		
Course Learning Outcomes	At the end of this course, the student should be able to use futuristic strategies to create innovative approaches. use innovative and creative thinking techniques in professional life.		
Assessment		**NUMBER**	**PERCENTAGE**
	Midterm Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	25
	Presentations and Reports (Interactive Team Work, Social Skills Development, based on subjects studied during classes and applications of them on MED areas & discussions after each presentation)	1	25
	Attendence (Showing interest to classes, performance during discussion times, performance during pair works, attending classes etc.)		5
	Quiz ((Short quizzes to keep students updated about lectures, prepare them to midterm & final, based on subjects studied in the class, Essay or MCQ)	5	5
	Final Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	40
	Total	8	**100**

Code	Subject		
MED 621	**Epidemiological Research and Evidence Based Medicine**		
Goals	The aim is to provide understanding of epidemiological language and terminology by reading, examining and discussing various types of epidemiological research papers and to develop the desire and enthusiasm for epidemiological studies.		
Content	Different sessions for each type of epidemiological research will be held. The selected research types are case report, cross-sectional, case- control, cohort study, and randomized controlled trial.		
Course Learning Outcomes	At the end of this course, the student should be able to comprehend various types of epidemiological research. explain basic epidemiological terminology.		
Assessment		**NUMBER**	**PERCENTAGE**
	Group work performance		50
	Presentations		50
	Total		**100**

Code	Subject		
MED 622	**Application of Economics in Health Care**		
Goals	This course aims to teach the essentials of economics and its' core concepts' relevance with health-care.		
Content	Tools and concepts of traditional Microeconomics Theory, health production function, cost & benefit analysis, demand for health insurance and health care markets.		
Course Learning Outcomes	At the end of this course, the student should be able to • explain the applications of micro-economic theories in health related areas. • discuss the causes of market failure. • list the factors effecting the demand for health. • explain health insurance supply and demand. • analyse how health care market operates.		
Assessment		**NUMBER**	**PERCENTAGE**
	Mid-terms	1	80
	Quizzes, Homeworks	5	5
	Attendance	14	15
		Total	100
	Contribution of Final Examination to Overall Grade		45
	Contribution of In-Term Studies to Overall Grade		55
		Total	100

Code	Subject		
MED 629	**Music and Medicine**		
Goals	This course aims to convey the past and current uses and utilities of music in medicine.		
Content	The connection of music and medicine throughout the historical development of antiquity and Middle Ages up until today. The place of music in medical practice after the transformations in the Age of Enlightenment and beyond.		
Course Learning Outcomes	At the end of this course, the student should be able to • explain the uses of medicine in the past and present. • describe the uses of music in clinical conditions, and before and after surgical treatment. • explain the effects of music before and after surgery • describe the types of music used in music therapy		
Assessment		**NUMBER**	**PERCENTAGE**
	Midterm	1	25
	Assignments (Homework)	1	25
	Final Exam		50
		Total	100
	Contribution of Final Examination to Overall Grade		50
	Contribution of In-Term Studies to Overall Grade		50
		Total	100

Code	Subject
MED 630	**Health Law**
Goals	The aim of the course is that students obtain a legal rationale, take ethical decisions from a legal perspective, act in a respectful way to patients' rights, legal risks and responsibilities.
Content	The basic concepts of law will be introduced with a view towards health law. The legal nature of medical interventions, concepts of malpractice and complication will be explained. The fundamentals and consequences of legal and criminal liability will be emphasized and medical interventions showing ethical, and legal characteristics will be evaluated from a legal point of view.
Course Learning Outcomes	At the end of this course, the student should be able to • analyze legislature and by-laws related to health law • distinguish branches and consequences of legal responsibility • in taking decisions about patients, help them to make their own decisions in a proper way by respecting their right to self-determination and their privacy. • take ethical decisions from a perspective of patients' rights and legal responsibility • identify legal risks in the developing areas of health law

		NUMBER	PERCENTAGE
Assessment	Assignment / presentation	1	50
	Final EXAM	1	50
		Total	100
	Contribution of Final Examination to Overall Grade		50
	Contribution of In-Term Studies to Overall Grade		50
		Total	100

Code	Subject
MED 631	**Creative Drama II**
Goals	This course aims the development of body awareness, improvement of communication skills of students by creating an atmosphere where the students can explore the potential of their emotional intelligence.
Content	In this class, the students will be searching for their abilities for self-representation and being visible in society and going into an active learning process by experiencing image theatre, invisible theatre, newspaper theatre and forum theatre techniques
Course Learning Outcomes	At the end of this course, the student should be able to • build supportive relationships in group by improving personal cooperating skills. • recognize personal awareness, • explain and review the schemes of personal attitude, thought and feeling by playing games and different roles. • improve critical and creative ways of thinking skills, also improve skills for life-long learning which will be useful for professional life as well as personal life. • explore being visible and expressing oneself in front of spectators using games and storytelling techniques.

		NUMBER	PERCENTAGE
Assessment	Midterm	1	25
	Performance evaluation	5	25
	Final EXAM		50
		Total	100
	Contribution of Final Examination to Overall Grade		50
	Contribution of In-Term Studies to Overall Grade		50
		Total	100

Code	Subject
MED 634	**Case Based Forensic Sciences**
Goals	This course aims to increase the awareness of students about forensic cases by presenting them as real case presentations through forensic sciences, where some of the patients that they will examine routinely in their professional lives are forensic cases.
Content	In each lecture, brief introduction information about one of the basic forensic sciences will be given, and with the help of this forensic science, how the case is elucidated and how the process is managed, will be explained in the lectures.
Course Learning Outcomes	At the end of this course, the student should be able to • give preliminary information about what the forensic sciences are, and their relationship with medicine and each other. • give examples an idea about the types of forensic cases they may encounter in their professional routine. • gain the awareness that every patient that they examine can turn into a forensic case. • explain the liability of healthcare professionals against forensic cases and what kind of problems both patients and healthcare professionals may encounter if they are omitted. • give preliminary information about the management process of the forensic case. • explain the importance of the holistic approach in the management of forensic cases • explain the importance of professionalization and coordination in forensic science.

Assessment		**NUMBER**	**PERCENTAGE**
	Assignments	1	50
	Final EXAM	1	50
		Total	100
	Contribution of Final Examination to Overall Grade		50
	Contribution of In-Term Studies to Overall Grade		50
		Total	100

OVERVIEW OF THE YEDİTEPE UNIVERSITY UNDERGRADUATE MEDICAL EDUCATION PROGRAM

Please see the below links to access Yeditepe University Medical School Undergraduate Medical Education Program's Information Package, Curriculum, and Detailed Course Plans in compliance with European Higher Education Area and Bologna Process regulations. These documents will provide you with a comprehensive overview of the program.

Faculty Website Links (Turkish):

- Curriculum: https://med.yeditepe.edu.tr/tr/mezuniyet-oncesi-tip-egitimi
- Bologna information Package: https://med.yeditepe.edu.tr/tr/bologna

Faculty Website Links (English):

- Curriculum: https://med.yeditepe.edu.tr/en/mezuniyet-oncesi-tip-egitimi
- Bologna information Package: https://med.yeditepe.edu.tr/en/bologna

COURSE LOCATIONS

COURSE CODES	COURSE NAMES	LOCATIONS
MED 302	INTRODUCTION to CLINICAL SCIENCES	**Lectures/Sessions/Panels:** Room Number: B311, Base Floor, Medical Faculty Block, Yeditepe University Campus. **Microbiology Laboratory:** Room Number: 934, 5th Floor, Medical Faculty Block, Yeditepe University Campus. **Pathology Laboratory:** Room Number: 929-930, 5th Floor, Medical Faculty Block, Yeditepe University Campus.
MED 303	INTRODUCTION to CLINICAL PRACTICE	**ICP-CSL:** Room Number: 442, Base Floor, Medical Faculty Block, Yeditepe University Campus. **YH:** Yeditepe University Hospital.

Yeditepe University Campus Address: İnönü Mah. Kayışdağı Cad. 26 Ağustos Yerleşimi, 34755, Ataşehir, İstanbul.

Yeditepe University Hospital Address: İçerenköy Mah. Hastane Yolu Sok. No:102-104. Ataşehir, İstanbul.

* Elective courses locations will be announced later.

SPECIFIC SESSIONS / PANELS

Introductory Session

Aim of the session:
The session provides basic information about Yeditepe University Faculty of Medicine Undergraduate Medical Education Program (YUFM/UG-ME) and the educational phase relevant to the students. This session orients the students to the program and the phase.

Objectives of the Session:
1. To provide basic information about the YUFM/UG-ME.
2. To provide basic information about the phase.
3. To provide essential information on social programs and facilities.

Rules of the Session:
1. The session will be held in two types, conducted by Phase Coordinator and Committee Coordinator, respectively.
2. The first type will be held once in the first week of the educational phase. The second type will be held at the beginning of each committee.
3. Students should attend the session.

Implementation of the Session:
In the first type, Phase Coordinator will present brief information on the following topics:
- Organizational Chart of Yeditepe University Faculty of Medicine Undergraduate Program (YUFM/UG-ME), Work Descriptions and Introduction of Committees Members,
- Directives on YUFM/UG-ME,
- YUFM/UG-ME Program Outcomes
- Learning Objectives of the Phase
- Academic Program of the Phase
- Teaching and Learning Methods
- Learning Environments and Sources/Resources
- Attendance
- Elective Courses (only in Phase I and Phase II)
- Assessment Procedure
- Grade Point Average, Cumulative Grade Point Average (GPA, cGPA) Calculation
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

In the second type, Committee Coordinator will present brief information on the following topics:
- Learning Objectives of the Committee
- Academic Program of the Committee
- Teaching and Learning Methods
- Learning Environments and Sources/Resources, References
- Attendance
- Assessment Methods and Question Distribution Table
- Committee Score Calculation Method
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

Committee Evaluation Session

Aim of the Session:

The aim of the session is to evaluate the committee educational program, with all its components, by the students and the committee coordinators. This session will contribute to the improvement of the educational program in general by giving the opportunity to identify the strengths of the committee educational program and revealing the areas which need improvement.

Objectives of the Program Evaluation Session are to;

- establish a platform for oral feedbacks in addition to the systematically written feedback forms
- give the opportunity to the students and the coordinators to discuss the committee period face to face
- allow the students to review the committee exam questions together with faculty members.

Process:

The total duration of the session is 90 minutes and the session consists of two parts. The first part (30 minutes) is dedicated to oral feedback by the students. All of the oral feedback will be recorded and reported by the committee coordination team. In the second part (60 minutes) committee exam questions will be reviewed and discussed by students and faculty.

Rules of the Committee Evaluation Session:

1. The **Committee Evaluation Session** will be held on the last day of each committee after the committee exam.
2. Students are required to attend the session.
3. The Committee coordinator will lead the session.
4. The faculty members who had contributed questions in the committee exam should attend the session.
5. Students must comply with the feedback rules while giving verbal feedback and all participants shall abide by rules of professional ethics.

Committee Improvement Session

Aim:

The aim of this session is sharing the program improvements based on the evaluation of the educational program data, with the students and the faculty members.

Objectives:

1. To share the improvements within educational program with the students and the faculty members.
2. To inform the students and the faculty members about the processes of the program improvement
3. To encourage student participation in the program improvement processes.

Rules:

1. Program improvements session will be implemented once a year. The implementation will be performed at the begining of the spring semester.
2. Students are required to attend the session.
3. The phase coordinator will monitor the session. If necessary the dean, vice deans and heads of the educational boards will attend to the session.
4. All faculty members will be invited to the session.

Implementation:

Before the Session

1. Phase coordinator will report the results of the improvements of the educational program.
2. The program improvements report has three parts. The first part of the report includes improvements that have been completed, and those that are currently in progress. The second part of the report includes, improvements that are planned in medium term, and the third part of the report includes, improvements that are planned in the long term.
3. The program improvements report also includes the program evaluation data (student feedbacks, faculty feedbacks, results of the educational boards meetings etc.) in use of improvements.

During the Session

4. The phase coordinator will present the program improvements report to the students and the faculty members.
5. Students can ask questions about, and discuss, the results of the program improvement.

Process: The total period of session is 30 minutes and has two parts. The first part (15 minutes) covers, presenting of the program improvement report. The second part (15 minutes) covers, students' questions and discussion.

After the Session

6. The program improvement brief will be published on the website of Yeditepe University Faculty of Medicine (http://med.yeditepe.edu.tr).

Multidisciplinary Case Discussion Panel

Aim:
The aim of this instructional method is, to integrate what students learnt during committee, to fit in the clinical context and to promote deep learning.

Objectives:
1. To relate learning objectives of the committee,
2. To relate clinical cases and learning subjects,
3. To explain learning objectives in the resolution of clinical cases,
4. To value the importantance of multidisiplinary study in the resolution of clinical cases.

Implementation:

Before the Panel
1. Case/cases that will be discussed in the panel will be chosen by a multidisiplinary team, in compliance with committee learning objectives.
2. The resources to analyse the cases will be specified by multidisiplinary team.
3. Students can get hard copies of the cases and the list of sources from student affairs at the beginning of the committee.
4. Students shall study cases in the context of learning objectives before the panel.
5. Before the panel, students may consult the faculty members for information about cases.

During the Panel
6. Cases will be shared visually with students by the multidisiplinary team.
7. Possible resolution of cases will be shared and discussed with students by the multidisiplinary team.
8. After the resolution of cases, students can ask questions to faculty members about the commitee learning obcetives in the context of cases.

Process: The total duration of the Panel is 60 minutes and has 2 parts. The first part (40 minutes), covers the presentation of cases, resolution of cases, asking questions to students and discussion as suitable to learning objectives during the resolution by multidisiplinary team. The second part (20 minutes), covers students' questions and discussion.

After the Panel
9. Students may continue reviewing the cases in the context of committee learning objectives.
10. The multidisiplinary team will review the usefulness of cases as a learning tool in the context of committee learning objectives. "The Panel Report" will be written by the multidisiplinary team.

INDEPENDENT LEARNING

Description:
"Independent learning" is a process, a method and a philosophy of education in which a student acquires knowledge by his or her own efforts and develops the ability for inquiry and critical evaluation. It includes freedom of choice in determining one's learning objectives, within the limits of a given project or program and with the aid of a faculty adviser. It requires freedom of process to carry out the objectives, and it places increased educational responsibility on the student for the achieving of objectives and for the value of the goals (1).

Aim:
The aim of this instructional strategy is to develop the students' ability, to learn individually, so they are prepared for the classroom lessons, lectures, laboratory experiences and clinical practices, exams, professional life and have the abilities needed for lifelong learning.

Objectives:
With this instructional strategy, students will develop;

- the skills that will help them to learn independently.
- self-discipline in their work habits.
- their evidence based research skills by using reliable resources.
- their teamwork skills by studying together.
- their clinical skills as self-directed working in the clinical skills laboratory.

Rules:
1. All of the students will define independent learning process according to below algorithm.
2. All of the students will be required to fill out a form, which is a self-assessment form for the independent learning (methodology: timing, sources, strategy, etc.).
3. The students' academic performance and independent learning methodology will be analyzed comparatively, and feed-back on further improvements will be provided.

What a student should do for learning independently?
1. **Analyzing:** First you will need to analyze carefully, what your problems and weaknesses are. For example, if you are studying anatomy, is your weak area broadly upper limb, lower limb, or what?
2. **Addressing:** Once you've decided your specific problems, you can list them. Which one needs to be addressed urgently? Work out your priorities. Whatever your subject area is, don't be afraid to return to the basics if necessary. It may give you more confidence in the long run to ensure you have a proper understanding of basic concepts and techniques.
3. **Accessing:** If you need reliable information, or if you need to read about a subject and put it into context, a textbook may be the best place to start. However, the Internet may be helpful if you need very up-to-date information, specific facts, or an image or video etc. If you need an academic research article, reports or case studies for your topic, then a database (Pubmed etc.) would be the best option.
4. **Timing:** In the weekly syllabus you will see, a specific time called "independent learning hour" for your independent work. In addition to these hours, the students should also have their own time schedule for their study time at home.
5. **Planning:** Your next step will be to work out a realistic study-plan for your work. What goals could you literally set for yourself? Don't make them too ambitious but set minor goals or targets that you know you will be able to achieve without having to spend a very long time working on them. How many hours will you need to achieve them? How will you know when you've achieved them?
6. **Recording:** When you work independently, it's a good idea to keep a written record of the work you've done. This can help with further planning and also give a sense of achievement as well as provide something to include in a progress file. As time goes by you may surprise yourself with what you've been able to achieve. This could motivate you to keep going, as could increase your confidence, and even improve your results
7. **Reflecting:** Reflecting on what you've done can help you decide whether the activity was really effective, whether an alternative approach might be better on another occasion, whether you spent the right amount of time and whether you have achieved the target you'd set yourself.
8. **Improving:** Once you've achieved the target, the process of planning can start again. Your needs and priorities may have changed, so think about them and then set yourself to another target.

EXAM RULES

- **Seating-** Students will be seated by the exam observers or proctors. Students are not allowed to change their seats without permission.
- **Electronics** – During examinations or tests, students are prohibited from using electronic devices or any other means of communication and recording that have not been approved beforehand. All electronic devices are prohibited. Anyone who fails to comply with these regulations may be charged with academic fraud.
- **Absence** – No additional time will be given to students who are absent for part of the exam, regardless of the reason for their absence.
- **Scratch Paper** – Students are not allowed to bring scratch paper into the exam room.
- **Meaning of Questions** – Students may not consult the supervisor as to the meaning of any question.
- **Signature** – Students must sign their multiple-choice answer sheets and/or written-answer sheets.

- **Other Activities Requiring Disciplinary Action**-
    - Students must not give or receive Asstance of any kind during the exam.
    - Gaining access to exam questions before the exam.
    - Using an unauthorized calculator or other mechanical aid that is not permitted.
    - Looking in the exam book before the signal to begin is given.
    - Marking or otherwise writing on the exam book or answer sheet before the signal to begin is given.
    - Making any changes, additions, deletions or other marking, erasing or writing on the exam book or answer sheet after the time for the exam has expired.
    - Having access to or consulting notes or books during the exam.
    - Looking at or copying from another student's paper.
    - Enabling another student to copy from one's paper.
    - Talking or otherwise communicating with another student during the exam or during the read through period.
    - Disturbing other students during the exam.
    - Consulting other persons or resources outside the exam room during the exam.
    - Copying questions or answers either on paper or with an electronic device to take from the exam room.
    - Taking an exam book or other exam materials from the exam room.
    - Taking an exam in place of another student.
    - Arranging to have another person take an exam for the student.
    - Disobeying to the conduct of supervisor during the exam.
    - Disclosing the contents of an exam to any other person.
    - Failing to remain in the exam room for a given period of time by the supervisors.
    - Failing to follow other exam instructions.

Those students found to have committed academic misconduct will face administrative sanctions imposed by the administration of Yeditepe University Faculty of Medicine according to the disciplinary rules and regulations of the Turkish Higher Education Council (YÖK) for students (published in the Official Journal on August 18th, 2012). The standard administrative sanctions include, the creation of a disciplinary record which will be checked by graduate and professional life, result in grade "F" on the assignment, exams or tests or in the class. Students may face suspension and dismissal from the Yeditepe University **for up to one school year**. In addition, student may loose any academic and non academic scholarships given by the Yeditepe University **for up to four years**. The appropriate sanctions are determined by the Yeditepe University administration according to egregiousness of the Policy violation.

ONLINE EXAM RULES

1. The online examination application of the Education Management Information System (EYS) works with connection to the internet. During your exam, you should take the exam in a quiet area where you have an internet connection.

2. You are not allowed to take the online exam from places that are not suitable for the exam such as private cars, public transportation vehicles, cafes, etc. You are expected to take the online exam in your own home, if possible, in your own study room.

3. During the online exam, connect to the Internet at a location near your wireless modem or, if possible, using the LAN cable to avoid network problems.

4. Online exam lenght, number of questions and question types will be announced by coordinators (preclinical years) or educational supervisors (clerkships).

5. You can use a desktop or laptop computer for the exam. Google Chrome should be used as an internet browser.

6. First of all, you need to register your computer with your Yeditepe e-mail address at **tf.yeditepe.edu.tr/online_sinav/** You can attend your online exam only from the registered (IP address is registered) computer.

7. You must be ready by entering the system 30 minutes before the specified time for the online exam.

8. Before starting the exam, you must connect to the Google Meet session from the link which will be delivered by the Coordinator. The online exam will be recorded with the Google Meet.

9. Identity check will be done before the exam starts. For this reason, you should have your student IDs with you.

10. When you enter the online exam system, you will be asked to switch the program in full screen mode and continue with it. How to switch to full screen mode and which key combinations to use for this will be indicated on the online exam screen.

11. Your computer's camera should be turned on during the exam.

12. The total time which is given to you for the exam will be displayed on the screen. In other words, after recording your answer, you will be able to move on to the next question without waiting.

13. After selecting your choice, do not forget to save it from the confirmation button.

14. You can answer the questions in the order you want. You will be given the option to check your answers or to return to the question you left blank.

15. The order of the questions will be arranged differently for each student and will be displayed on the screen.

16. If you have disconnection to internet during the exam, you will be able to reconnect to the exam. In this case, you will be able to continue the exam from where you left off.

17. You will not be allowed to leave the computer during the exam (online exam process will be recorded through the Google Meet).

ONLINE EXAM ETHICAL RULES

*This rules also includes situations that will be considered as cheating during the exam.

During the exam, students, shall act honestly, and not to tend cheating to uphold the reputation of the medical student.

All students must have their cameras on and their microphones off during the exam. A healthy camera view is a requirement of the online exam. If this cannot be achieved with an integrated or external camera, students should download google meet to their mobile phones, join the observer links on their phones, and transmit their images with the phone's camera throughout the exam.

During the exam, It is forbidden;

1. to wear headphones,
2. to speak and / or to close the mouth to speak.
3. to go out of the camera view,
4. to use or attempt to use mobile phones etc.
5. to look outside the exam screen,
6. to take screenshots of the questions and share them electronically

Students who exhibit the above-mentioned behaviors will be warned by the observers. Despite the warnings, the exams of the students who constantly behave in this way will be considered invalid and these students will be regarded within the scope of the Student Disciplinary Regulations for Higher Education Institutions.

ASSESSMENT PROCEDURE

The Assessment Procedure of the Phase III covers exams and scores and their abbrevations that shown below.

- Exams:
  - Committee Exam (CE)
  - Mid-term Exam (MTE)
  - Final Exam (FE)
  - Incomplete Exam (ICE)
  - Make-up Exams (MUE)
- Scores*:
  - Committee Score (CS)
  - Committees Mean Score (CMS)
  - Introduction to Clinical Practice Score (ICPS)
  - Scientific Research and Project Course Score (SRPCS)
  - Final Exam Score (FES)
  - Incomplete Exam Score (ICES)
  - Term Score (TS)

* All scores have a range of 0-100 points.

Assessment approaches, assessment methods and assessment tools, that related with the exam and score types, are shown in below table.

Assessment Approaches	Assessment Methods	Question Types / Assessment Tools	Exams	Derived Scores
Knowledge-based Assessment	WE: Written Examination	MCQ: Multiple Choice Questions	CE, MTE, FE, ICE	CS, ICPS, FES, ICES
		EMQ: Extended Matching Questions	CE	CS
		FSAQ: Fill-in-the-Blank Short Answer Questions	MuE	CS
Competency–based Assessment	OSCE: Objective Structured Clinical Examination	OSCE Checklist		ICPS
Performance–based Assessment	PWPE: Project Writing and Presenting Evaluation	PWPE Checklist		SRPCS

Exams Information (MED 302, MED 303)	
CE	For the proportional correspondence of individual learning objectives, please see the committee's assessment matrix table/page.
FE	FE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
ICE	ICE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
MUE$_{ICS}$	MUE will be held only twice in a term. MUE consists of FSAQs. MUE content will be developed by the coordination committees.

Scores Information (MED 302, MED 303)	
CS	The committee score is based on various question types/numbers and/or assessment tools (MCQ, EMQ, MEQ or Checklists). Please see the committee's assessment matrix table/page for the specifications.
CMS	= Average of CSs
ICPS	= (50% Midterm) + (50% Final)
SRPCS	= Score information is shown in below Scientific Research and Project Course - III page.
FES	= Final Exam Score
ICES	= Incomplete Exam Score
TS *for students, who are exempted from FE*	= 98% of CMS + 2% of SRPCS
TS *for students, who are not exempted from FE*	= 98% of (60% of CMS + 40% of FES or ICES) + 2% of SRPCS

Pass or Fail Calculations of the Courses
INTRODUCTION to CLINICAL SCIENCES (ICS) III (MED 302)
Pass; *TS* **≥ *50***
Fail; *FES* **< *50*** *(barrier point), ICES* **< *50*** *(barrier point), or/and TS* **< *50***
The student is exempted from FE, if the CMS is **≥ *75*** *and all CSs are* **≥ *50***
The FE and ICE barrier point is not applied to the students whose all CSs are **≥ *50***
INTRODUCTION to CLINICAL PRACTICE (ICP) III (MED 303)
Pass; *ICPS* **≥ *50***
Fail; *ICPS* **< *50***

The Assessment Procedure of the Phase III will be announced and explained in the introductory session at the beginning of the academic year.

Definitions of the Assessment Methods and Question Types

MCQ consist of a question, followed by five plausible alternative responses from which the student has to select the correct one.

EMQ are similar to multiple choice questions but with one key difference, that they test knowledge in a far more applied, in depth, sense. EMQ is based on a single theme, two or more questions and has a long option list.

MEQ is made up of one or more short answer questions. The student is provided with basic science or clinical information and then asked to write brief responses to one or more questions. When a series of questions is presented, additional information about the original problem can be provided at each subsequent step, guiding the students through an analytical process.

FSAQ, Fill-in-the-Blank Short Answer Questions are typically composed of a brief prompt that demands a written answer that varies in length from one or two words to a sentence.

OSCE describes a form of competency-based testing used to measure a student's clinical competence. During an OSCE, students are observed and evaluated as they go through a series of stations in which they interview, examine and treat simulated patients who present with some type of medical problem.

ACADEMIC CALENDAR of PHASE III 2020 - 2021

INTRODUCTION to CLINICAL SCIENCES (MED 302)

COMMITTEE I

INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEMS (7 Weeks)

Beginning of Committee	October 5, 2020	Monday
End of Committee	November 20, 2020	Friday
Committee Exam	**November 20, 2020**	**Friday**
National Holiday	**October 28 1/2, 2020** **October 29, 2020**	**Wednesday, Thursday**
Commemoration of Atatürk	**November 10, 2020**	**Tuesday**

COMMITTEE II

CARDIOLOGY and RESPIRATORY SYSTEMS (7 Weeks)

Beginning of Committee	November 23, 2020	Monday
End of Committee	January 8, 2021	Friday
Committee Exam	January 8, 2021	**Friday**
New Year	**January 01, 2020**	**Wednesday**

COMMITTEE III

GASTROINTESTINAL SYSTEM (4 Weeks)

Beginning of Committee	January 11, 2021	Monday
End of Committee	February 19, 2021	Friday
Committee Exam	**February 19, 2021**	**Friday**
MIDTERM BREAK	**February 1 – 14, 2021**	

COMMITTEE IV

ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS (7 Weeks)

Beginning of Committee	February 22, 2021	Monday
End of Committee	April 9, 2021	Friday
Committee Exam	**April 9, 2021**	**Friday**
Physicians' Day	**March 14, 2021**	**Sunday**

COMMITTEE V

NERVOUS SYSTEM and PSYCHIATRY (7 Weeks)

Beginning of Committee	April 12, 2021	Monday
End of Committee	May 28, 2021	Friday
Committee Exam	**May 28, 2021**	**Friday**
National Holiday	**April 23, 2021**	**Friday**
Labour's Day	**May 01, 2021**	**Saturday**
Religious Holiday	**May 12 1/2 – 15, 2020**	**Wednesday-Saturday**
National Holiday	**May 19, 2020**	**Wednesday**

COMMITTEE VI
MUSCULOSKELETAL SYSTEM (5 Weeks)

Beginning of Committee	May 31, 2021	Monday
End of Committee	July 2, 2022	Friday
Committee Exam	**July 2, 2021**	**Friday**

SCIENTIFIC RESEARCH and PROJECT COURSE

Midterm Assesment	**Jan 15, 2020**	**Friday**
Final Assesment	**May 28, 2021**	**Friday**

INTRODUCTION to CLINICAL SCIENCES (MED 302):

Make-up Exam	**July 16, 2021**	**Friday**
Final Exam	**July 26, 2021**	**Monday**
Incomplete Exam	**August 16, 2021**	**Monday**

INTRODUCTION to CLINICAL PRACTICE – III (MED 303):

Beginning of ICP - III	October 19, 2020	Monday
End of ICP - III	June 14, 2021	Monday
Midterm Exam	**March 5, 2021**	**Friday**
Make-up Exam	**May 21, 2021**	**Friday**
Final Exam	**July 5-9, 2021**	**Monday - Friday**
Incomplete Exam	**July 30, 2021**	**Friday**

FREE ELECTIVE COURSES:

Beginning of Elective Courses	February 19, 2021	Friday
End of Elective Courses	June 04, 2021	Friday
Midterm Exam	**April 2, 2021**	**Friday**
Make-up Exam	**June 14 - 18, 2021**	**Monday-Friday**
Final Exam	**June 21-28 , 2021**	**Monday-Monday**
Incomplete Exam	**July 5-27, 2021**	**Monday-Tuesday**

COORDINATION COMMITTEE MEETINGS

1st Coordination Committee Meeting:	November 6, 2020	Friday
2nd Coordination Committee Meeting: (with student participation)	January 12, 2021	Tuesday
3rd Coordination Committee Meeting: (with student participation)	May 25, 2021	Tuesday

RECOMMENDED TEXTBOOKS

Biomedical Ethics & Deontology

1. Marcia Lewis, Carol D. Tamparo. Medical Law, Ethics, & Bioethics for the Health Professions, F.A. Davis Publishing House, 2012, ISBN: 0803627068
2. Michael Boylan. Medical Ethics, Wiley-Blackwell Publishing House, 2013, ISBN: 978-1118494752

Biostatistics

1. Pagano, Marcello, Gauvreau, Kimberlee. Principles of Biostatistics. Duxbury Press, 2000 ISBN 0534229026, 9780534229023.
2. Glantz, Stanton A. Primer of Biostatistics. 7th Edition. McGraw Hill Professional, 2011. ISBN 0071447814, 9780071447812.

Infectious Diseases and Clinical Microbiology

1. Murray, Patrick R, Rosenthal, Ken S, Pfaller, Michael A.. Medical Microbiology with STUDENT CONSULT Online Access. 8th Edition, 2016.

Medical Genetics

1. Turnpenny, Peter D, Ellard, Sian. Emery's Elements of Medical Genetics. 14th Edition. Churchill Livingstone, 2012, ISBN: 9780702040436

Neurosurgery

1. Microneurosurgery, Volume I to Volume V, Thieme Kindle Edition by Mahmut Gazi Yasargil (Author)
2. Neurology and Neurosurgery Illustrated, 5th Edition by Kenneth W. Lindsay PhD FRCS (Author), Ian Bone FRCP FACP (Author), Geraint Fuller MD FRCP (Author)
3. Handbook of Neurosurgery Feb 22, 2010 by Mark S. Greenberg

Pharmacology

1. Harvey, Richard A. Lippincott's Illustrated Review of Pharmacology. 6th ed., Wolters Kluwer Health, 2015. ISBN: 978-1469887562.
2. Katzung, Bertram G., Masters, Susan B., Trevor Anthony J. Katzung's Basic & Clinical Pharmacology. 14th Edition. McGraw Hill Companies, 2017. ISBN: 978-1259641152.
3. Brunton, Laurence, Chabner, Bruce, Knollman, Bjorn. Goodman&Gilman's The Pharmacological Basis of Therapeutics. 13th Edition. McGraw Hill Companies, 2017. ISBN: 978-1259584732.

Orthopedic Surgery

1. Ortopedik Fizik Muayane, çeviri ed. Uğur Şaylı, Güneş Tıp Kitapevi
2. Review of Orthopaedics, 6th edition (ed. Mark D. Miller)
3. AAOS Comprehensive Orthopaedic Review, 2nd edition (ed. Martin I. Boyer)

Pathology

1. Abbas Aster, Kumar. Robbıns Basıc Pathology. 9th edition, Saunders, Elsevıer Inc. 2013. ISBN:978-0-8089-2432-6

Psychiatry

1. Öztürk O. Ruh Sağlığı ve Bozuklukları. 2. Baskı, Ankara 2011. ISBN: 9786058617292
2. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9. Ed. 2009, Lippincott Williams & Wilkins, PA, USA. ISBN: 9780781768993
3. Purves D, Augustine GJ. Fitzpatrick D. et al. Neuroscience. 5. Ed. 2012, Sinauer Assoc, Mass, USA. ISBN: 9780878936953

General Surgery

1. Brunicardi, F. Schwartz's Principles of Surgery, 10th edition, July 16, 2014, ISBN: 0071796754 / 9780071796750

Urology

1. Campbell-Walsh Urology, 11th Edition 4-Volume Set. By Alan J. Wein, MD, FACS, PhD (hon), Louis R. Kavoussi, MD, Alan W. Partin, MD, PhD and Craig A. Peters, MD, FACS, FAAP. Imprint: Elsevier. ISBN: 978-1-4557-7567-5. Copyright: 2016

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM

DISTRIBUTION of LECTURE HOURS

October 5, 2020 - November 20, 2021

COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	INFECTIOUS DISEASES	ID	20				**20**
	MEDICAL MICROBIOLOGY	MM	10		2 X 1=2 (4 Groups)		**12**
	PHARMACOLOGY	PC	21				**21**
	PATHOLOGY	PT	12			2	**14**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	12				**12**
	HEMATOLOGY	HEM	11				**11**
	PUBLIC HEALTH	PH	8				**8**
	IMMUNOLOGY	IMM	6				**6**
	MEDICAL GENETICS	MG	5				**5**
	PEDIATRICS	PED	4				**4**
	PATHOPHYSIOLOGY	PP	4				**4**
	PHYTOTHERAPY	PHY	3				**3**
	BIOSTATISTICS	BS	3				**3**
	ONCOLOGY	ONC	3				**3**
	FAMILY MEDICINE	FM	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		124		2	4	**130**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				2	**2**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			2 X 3=6 (4 Groups)		**6**
TOTAL			**124**		**8**	**6**	**138**
	INDEPENDENT LEARNING						**107**

Coordination Committee

HEAD	Meral Sönmezoğlu, MD, Prof.
SECRETARY	Ayşegül Kuşkucu, MD, Assist. Prof.
MEMBER	Ece Genç, PhD, Prof.
MEMBER	Ferda Özkan, MD, Prof.
MEMBER	Atilla Özkan, MD, Assoc. Prof.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD, Prof.
MEDICAL MICROBIOLOGY	İ. Çağatay Acuner, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof
PATHOLOGY	Aydın Sav, MD, Prof.
HEMATOLOGY	Atilla Özkan, MD, Assoc.Prof.
PEDIATRICS	Sabri Kemahlı, MD, Prof S. Perihan Saf, MD
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, Assoc. Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Assist Prof.
BIOISTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof. M. Engin Celep, PhD, Assist. Prof.
ONCOLOGY	Okan Kuzhan, MD, Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Zeynep Alkan, MD, Assoc. Prof. Serdar Özdemir, MD, Assist. Prof.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM
AIMS and LEARNING OBJECTIVES

INFECTIOUS DISEASES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. ***to convey*** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. ***to convey*** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. ***to convey*** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. ***to convey*** biostatistical knowledge required in design of medical research,
10. ***to convey*** necessary knowledge on genetical basis of clinical conditions,
11. ***to equip with*** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0 ***explain*** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

2.0 ***recall*** structures, and

2.1. ***explain*** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

3.0 ***classify*** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,

4.0 ***explain*** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

5.0 ***explain*** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

6.0 ***explain*** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

7.0 ***explain*** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,

8.0 ***explain*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

9.0 at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:

9.1. practice of history taking and physical examination
9.2. evaluation of emergency case (sepsis and septic shock)
9.3. approach to healthy individual or patient (fever)
9.4. laboratory tests/examinations (urine sample collection, urine strip/dipstick test, urine culture)
9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases)
9.6. point of care testing (urine strip/dipstick test)
9.7. making preliminary diagnosis or definitive diagnosis decision
9.8. making non-intervention or intervention decision
9.9. practicing non-intervention or intervention
9.10. referral/transport of healthy individual or patient

10.1. ***list*** goals and principles of drug use,
10.2. ***describe*** effects,
10.3. ***explain*** mechanism of action (pharmacodynamics),
10.4. ***list*** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug inreactions and side effects,
10.5. ***explain*** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antihelmintic drugs, antiseptics and disinfectants) used in infectious clinical conditions,

11.0 ***explain*** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,

12.0 ***define*** approaches (education, santitation, hygiene, disinfection/antisepsis/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,

13.0 ***explain*** hereditary immune system disorders,

14.0 ***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,

15.0 ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,

16.0 ***perform*** basic clinical skills, practiced on phantom models (suturing technique), required at primary health care service level.

HEMATOPOIETIC SYSTEM

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of hematopoietic system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. ***to convey*** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. ***to convey*** basic knowledge on phytotherapy
10. ***to convey*** knowledge on comparative biostatistical analysis of study groups,

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

H1. ***recall*** anatomy, histology and physiology of hematopoietic system,

H2. ***explain*** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,

H3. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,

H4. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,

H5. ***describe*** mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,

H6. at multi-system level and/or related to hematopoietic system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

H6.1. practice of history taking and physical examination
H6.2. evaluation of emergency case
H6.3. approach to healthy individual or patient (anemia, lymphadenopathy)
H6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests, hematology tests for anemia)
H6.5. imaging tests/examinations (nuclear medicine tests in hematology)
H6.6. point of care testing (hematology-peripheral blood smear examination, hematology-complete blood count)
H6.7. making preliminary diagnosis or definitive diagnosis decision
H6.8. making non-intervention or intervention decision
H6.9. practicing non-intervention or intervention
H6.10. referral/transport of healthy individual or patient
H7. ***classify*** blood products and blood groups,
H8. ***define*** principles of transfusion,
H9. ***explain*** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
H10. ***explain*** mechanisms of bone marrow toxicity of drugs and other chemicals,
H11. ***list*** principles of cancer chemotherapy,
H12. ***explain*** chemotherapy in leukemia and lymphoma,
H13. ***list*** phytotherapeutic agents with immunomodulatory effects,
H14. ***list*** principles of comparative biostatistical analysis of study groups,
H15. ***explain*** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM
COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MED 302 INTRODUCTION to CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**DISCIPLINE**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0 -12.0, H7, H8	ID	M. Sönmezoğlu	14	6	6	26
1.0 -12.0	MM	İ. Ç. Acuner	7	3	3	13
10.0, H9, H10	PC	E. Genç E.N. Özdamar	15	4	4	23
4.0.,5.0, H2	PT	A. Sav	9	4	4	17
14.0	BED	E. Vatanoğlu Lutz	9	4	4	17
H1 – H7	HEM	H. A. Özkan	8	3	3	14
6.0.,7.0.,11.0.,12.0.	PH	R. E. Sezer H. A.Taşyıkan	6	2	2	10
4.0, 5.0, 13.0	IMM	G. Y. Demirel	4	2	2	8
14.0.	MG	A. Ç. Kuşkucu	4	2	2	8
8.0.,9.0., 9.1.	PED	S. Kemahlı P. Saf	4	2	2	8
4.0.,5.0.,8.0, H1, H2	PP	M. Kaçar	2	1	1	4
H13 – H15	PHY	E. Yeşilada	2	1	1	4
15.0., H14	BS	Ç. Altunok	2	1	1	4
H2, H11, H12	ONC	O. Kuzhan	2	1	1	4
9.0, 11.0	FM	G. İzbırak	1	0	0	1
9.2	EM	M. F. Çelikmen	1	0	0	1
TOTAL			90	36	36	162
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (EMQ)**			
1.0 -12.0, H7, H8	IDCM	M. Sönmezoğlu	2	-	-	2
H1 – H7	HEM	H. A. Özkan	2	-	-	2
4.0.,5.0, H2	PT	A. Sav	1	-	-	1
		TOTAL	5	-	-	5

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

****39** out of 200 FE and ICE MCQs will be from Committee I (Each question is of worth **0.5** pts).

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM

WEEK I / 5 – 9 Oct 2020

	Monday 5-Oct--2020	Tuesday 6-Oct--2020	Wednesday 7-Oct--2020	Thursday 8-Oct--2020	Friday 9-Oct--2020
09.30- 09.50	**Introduction to Phase III**	**Lecture** Beneficence and Non-Maleficence E. Vatanoğlu Lutz	**Lecture** Antimicrobial Agents: Mechanisms of Resistance I İ.Ç. Acuner	**Lecture** Laboratory Diagnosis of Infectious Diseases IV İ.Ç. Acuner	**Lecture** ß Lactam Antibiotics I E. Genç
10.00- 10.50	**Lecture** Laboratory Diagnosis of Infectious Diseases I İ.Ç. Acuner	**Lecture** Transplantation E. Vatanoğlu Lutz	**Lecture** Antimicrobial Agents: Mechanisms of Resistance II İ.Ç. Acuner	**Lecture** Laboratory Diagnosis of Infectious Diseases V İ.Ç. Acuner	**Lecture** ß Lactam Antibiotics II E. Genç
11.00- 11.50	**Lecture** Laboratory Diagnosis of Infectious Diseases II İ.Ç. Acuner	**Lecture** Principles of Autonomy and Informed Consent E. Vatanoğlu Lutz	**Lecture** Introduction to Antimicrobial Chemotherapy E. Genç	**Lecture** Antimicrobial Agents: Basic Concepts & Principles I İ.Ç. Acuner	**Independent Learning**
12.00- 12.50	**Lecture** Laboratory Diagnosis of Infectious Diseases III İ.Ç. Acuner	**Lecture** Justice in Medicine E. Vatanoğlu Lutz	**Lecture** Vancomycin & Other Cell Wall Synthesis Inhibitors E. Genç	**Lecture** Antimicrobial Agents: Basic Concepts & Principles II İ.Ç. Acuner	**Independent Learning**
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Case Discussion on Immunity to Infection G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**	**Lecture** Public Health and Communicable Diseases-I R.E. Sezer	**Independent Learning**
15.00- 15.50	**Lecture** Case Discussion on Immunity to Infection G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**	**Lecture** Public Health and Communicable Diseases-**II** R.E. Sezer	
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK II / 12-16 Oct 2020

	Monday 12-Oct--2020	Tuesday 13-Oct--2020	Wednesday 14-Oct--2020	Thursday 15-Oct--2020	Friday 16-Oct--2020
09.00- 09.50	**Lecture** Introduction to Clinical Oncology O. Kuzhan	**Lecture** Hospital Infection M. Sönmezoğlu	**Lecture** Planning Medical Studies I Ç. Altunok	**Lecture** Occupational Health Hazards I M. Sönmezoğlu	**Lecture** Aminoglycosides E. Genç
10.00- 10.50	**Lecture** Pathophysiology of Infectious Diseases I M. Kaçar	**Lecture** Febril Neutropenia M. Sönmezoğlu	**Lecture** Planning Medical Studies II Ç. Altunok	**Lecture** Occupational Health Hazards II M. Sönmezoğlu	**Lecture** Sulfonamides, Chloramphenicol & Tetracyclines E. Genç
11.00- 11.50	**Lecture** Pathophysiology of Infectious Diseases II M. Kaçar	**Lecture** Bacterial and Viral Skin & Soft Tissue Infections M. Sönmezoğlu	**Lecture** Research Design Ç. Altunok	**Lecture** Vaccines M. Sönmezoğlu	**Lecture** Prevention and Control of Communicable Diseases I R.E. Sezer
12.00- 12.50	**Lecture** Pathophysiology of Infectious Diseases III M. Kaçar	**Lecture** Infections in Immuncompromised Host M. Sönmezoğlu	**Lecture** Antimycobacterial Drugs E. Genç	**Lecture** Pathology of Mycobacterial Infections A. Sav	**Lecture** Prevention and Control of Communicable Diseases II R.E. Sezer
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Zoonotic Diseases I M. Sönmezoğlu	**Lecture** Phytotherapy I E. Yeşilada	**Lecture** Lenforeticular Infections I M. Sönmezoğlu	**Lecture** Transplantation Immunology G. Yanıkkaya Demirel	**Independent Learning**
15.00- 15.50	**Lecture** Zoonotic Diseases II M. Sönmezoğlu	**Lecture** Phytotherapy II E. Yeşilada	**Lecture** Lenforeticular Infections II M. Sönmezoğlu	**Lecture** Transplantation Immunology G. Yanıkkaya Demirel	
16.00- 16.50	**Lecture** Fungal and Parasitic Skin and Soft Tissue Infections M. Sönmezoğlu	**Lecture** Phytotherapy III E. Yeşilada	**Lecture** Tuberculosis & Other Mycobacterial Infections I M. Sönmezoğlu	**Lecture** Blood Components and Transfusion Indications M. Sönmezoğlu	
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Tuberculosis & Other Mycobacterial Infections II M. Sönmezoğlu	**Lecture** Blood Groups M. Sönmezoğlu	

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK III / 19-23 Oct 2020

	Monday 19-Oct--2020	Tuesday 20-Oct--2020	Wednesday 21-Oct--2020	Thursday 22-Oct--2020	Friday 23-Oct--2020
09.00- 09.50	**Case Discussions** Pathology Tissue Response to Infections A. Sav	**ICP** (Ear-Nose-Throat Examination) Z. Alkan / S. Özdemir	**Lecture** Introduction to Clinical Oncology I O. Kuzhan	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Case Discussions** General Rewiev of Pathology of Infections Disease A. Sav	**Group A IL** / **Group B IL** / **Group C** Small Group Study SRPC / **Group D ICP**	**Lecture** Introduction to Clinical Oncology II O. Kuzhan	**ICP** (Ear-Nose-Throat Examination) Z. Alkan / S. Özdemir	**ICP** (Ear-Nose-Throat Examination) Z. Alkan / S. Özdemir
11.00- 11.50	**Microbiology Laboratory** (DiagnosticTests of Respiratory Specimens) Microbiology Instructors **Group A IL** / **Group B IL** / **Group D** / **Group C IL**		**Lecture** Treatment Approaches of Cancer O. Kuzhan	**Group A ICP** / **Group B** Small Group Study SRPC / **Group C IL** / **Group D IL**	**Group A** Small Group Study SRPC / **Group B ICP** / **Group C IL** / **Group D IL**
12.00- 12.50	**Group D IL** / **Group C**	**Lecture** Laboratory Diagnosis of Infectious Diseases VI (Advancements in Diagnostic Microbiology) İ. Ç. Acuner	**Lecture** Emergency Evaluation of Sepsis and Septic Shock M. F. Çelikmen		
12.50- 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP** (Ear-Nose-Throat Examination) Z. Alkan / S. Özdemir	**Lecture** Antiprotozoal Drugs E. N. Özdamar	**Independent Learning**	**Lecture** Antianemic Drugs E. Genç	**Independent Learning**
15.00- 15.50	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D** Small Group Study SRPC	**Lecture** Immunomodulators E. N. Özdamar	**Independent Learning**	**Lecture** Antihelminthic Drugs E. Genç	**Independent Learning**
16.00- 16.50		**Lecture** Approach to the Pediatric Patient with Fever P. Saf	**Independent Learning**	**Lecture** Pathology of Viral Infections I A. Sav	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Pathology of Viral Infections II A. Sav	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK IV / 26-30 Oct 2020

<table>
<tr><th></th><th>Monday
26-Oct--2020</th><th>Tuesday
27-Oct--2020</th><th>Wednesday
28-Oct--2020</th><th>Thursday
29-Oct--2020</th><th>Friday
30-Oct--2020</th></tr>
<tr><td>09.00- 09.50</td><td>Independent Learning</td><td>Lecture
Non/Hodgkin's Lymphoma I
Lecturer</td><td>Lecture
Pathology of Myeloproliferative Diseases I
Lecturer</td><td rowspan="4">NATIONAL HOLIDAY</td><td>Lecture
Introduction to the Course I
E. Vatanoğlu Lutz</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Pathology of Bone Marrow-1
Lecturer</td><td>Lecture
Non/Hodgkin's Lymphoma II
Lecturer</td><td>Lecture
Pathology of Myeloproliferative Diseases II
Lecturer</td><td>Lecture
Introduction to the Course II
E. Vatanoğlu Lutz</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Pathology of Bone Marrow-2
Lecturer</td><td>Lecture
Hematostatic Drugs and Hematostatic Blood Products I
E. Genç</td><td>Lecture
Lymphoreactive Disease
Lecturer</td><td>Lecture
Physician-Patient Relationship
E. Vatanoğlu Lutz</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Hodgkin’s Lymphoma
Lecturer</td><td>Lecture
Hematostatic Drugs and Hematostatic Blood Products II
E. Genç</td><td>Lecture
Pathology of Spleen
Lecturer</td><td>Lecture
Confidentiality and Truthfulness
E. Vatanoğlu Lutz</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Introduction to Anemias in Childhood
S. Kemahlı</td><td colspan="3">Microbiology Laboratory
(Antibacterial Susceptibility Testing)
Microbiology Instructors</td><td rowspan="3">NATIONAL HOLIDAY</td><td rowspan="3">NATIONAL HOLIDAY</td><td rowspan="2">Microbiology Laboratory
(Antibacterial Susceptibility Testing)
Microbiology Instructors</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Introduction to Hemolytic Anemias Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others)
S. Kemahlı</td><td>Group A</td><td>Grpup B IL</td><td>Group C IL</td><td>Group D IL</td><td>Group A IL</td><td>Grpup B IL</td><td>Group C</td><td>Group D IL</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Hemophilia and other Coagulopathies in Childhood
S. Kemahlı</td><td>Group A IL</td><td>Grpup B</td><td>Group C IL</td><td>Group D IL</td><td>Group C IL</td><td>Group D</td></tr>
<tr><td>17.00-17.50</td><td>Independent Learning</td><td colspan="3">Independent Learning</td><td>Independent Learning</td></tr>
</table>

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK V / 2-6 Nov 2020

	Monday 2-Nov-2020	Tuesday 3-Nov-2020	Wednesday 4-Nov-2020	Thursday 5-Nov-2020	Friday 6-Nov-2020
09.00- 09.50	**Lecture** Transhumanisms and Ethics E. Vatanoğlu Lutz	**Lecture** Myeloproliferative Diseases A. Özkan	**Lecture** Plasma Cell Dyscrasias A. Özkan	**Lecture** Quantitative and Qualitative Platelet Disorders A. Özkan	**Lecture** Semiology-I M. Sönmezoğlu
10.00- 10.50	**Lecture** Ethics of the Future/Future of Ethics E. Vatanoğlu Lutz	**Lecture** Chronic Leukemia A. Özkan	**Lecture** Hypercoagulability A. Özkan	**Lecture** Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia A. Özkan	**Lecture** Semiology-II M. Sönmezoğlu
11.00- 11.50	**Lecture** Bioethics E. Vatanoğlu Lutz	**Lecture** Aplastic and Hypoplastic Anemias A. Özkan	**Lecture** Immune Acquired Hemolytic Anemias / Non-Immune Acquired Hemolytic Anemias A. Özkan	**Lecture** Lymphoma A. Özkan	**Lecture** Parasitic Infections I M. Sönmezoğlu
12.00- 12.50	**Lecture** Responsible Biomedical Research E. Vatanoğlu Lutz	**Lecture** Nutritional Anemias A. Özkan	**Lecture** Introduction to the Program of Family Medicine G. İzbırak	**Lecture** Acute Leukemias A. Özkan	**Lecture** Parasitic Infections II M. Sönmezoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Ethics of Publication E. Vatanoğlu Lutz	**Lecture** Pathophysiology of Hematopoietic System Disorders I M. Kaçar	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel	**Lecture** Molecular Basis of Hemoglobinopathies A. Ç. Kuşkucu	**Lecture** How to Write a Project Report? B. Yılmaz / H. Taşyıkan
15.00- 15.50	**Microbiology Laboratory** (Diagnostic tests of respiratory specimens) Microbiology Instructors	**Lecture** Pathophysiology of Hematopoietic System Disorders II M. Kaçar	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel	**Lecture** Inherited Immune System Disorders A. Ç. Kuşkucu	**Lecture** Scientific Career and Preparation of CV B. Yılmaz / H. Taşyıkan
16.00- 16.50	**Group A** / **Group B IL** / **Group C IL** / **Group D IL**	**Lecture** Pathophysiology of Hematopoietic System Disorders III M. Kaçar	**Lecture** Introduction to Clinical Genetics A. Ç. Kuşkucu	**Lecture** Genetics of Oncology I A.Ç. Kuşkucu	**Independent Learning**
17.00-17.50	**Group A IL** / **Group B** / **Group C IL** / **Group D IL**	**Independent Learning**	**Independent Learning**	**Lecture** Genetics of Oncology II A.Ç. Kuşkucu	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VI / 9-13 Nov 2020

	Monday 9-Nov-2020	Tuesday 10-Nov-2020	Wednesday 11-Nov-2020	Thursday 12-Nov-2020	Friday 13-Nov-2020
09.00- 09.50	**Lecture** Antimalarial Drugs E. N. Özdamar	**Commemoration of Atatürk**	**Lecture** Macrolides E. N. Özdamar	**Lecture** Pharmacological Basis of Cancer Therapy I E. N. Özdamar	**Independent Learning**
10.00- 10.50	**Lecture** Quinolones E. N. Özdamar		**Lecture** Antiviral Drugs E. N. Özdamar	**Lecture** Pharmacological Basis of Cancer Therapy II E. N. Özdamar	**Independent Learning**
11.00- 11.50	**Lecture** Investigation of a Disease Epidemic I H.A.Taşyıkan		**Lecture** Antifungal Drugs E. N. Özdamar	**Multidisciplinary Case Discussion Panel**	**Independent Learning**
12.00- 12.50	**Lecture** Investigation of a Disease Epidemic II H.A.Taşyıkan		**Lecture** Antiseptics and Disinfectants E. N. Özdamar	**Multidisciplinary Case Discussion Panel**	**Independent Learning**
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Epidemiology of Communicable Diseases I H.A.Taşyıkan	**Commemoration of Atatürk**	**Independent Learning**	**Independent Learning**	**Independent Learning**
15.00- 15.50	**Lecture** Epidemiology of Communicable Diseases II H.A.Taşyıkan		**Independent Learning**	**Independent Learning**	**Independent Learning**
16.00- 16.50	**Independent Learning**		**Independent Learning**	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**		**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VII / 16-20 Nov 2020

	Monday 16-Nov-2020	Tuesday 17-Nov-2020	Wednesday 18-Nov-2020	Thursday 19-Nov-2020	Friday 20-Nov-2020
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					
11.00- 11.50					
12.00- 12.50					
13.00 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	COMMITTEE EXAM
15.00- 15.50					
16.00- 16.50					
17.00-17.50					**Program Evaluation Session** Committee I Coordination Committee Members

COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

DISTRIBUTION of LECTURE HOURS
November 23, 2020 –January 8, 2021
COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABB.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PHARMACOLOGY	PC	25				**25**
	PATHOLOGY	PT	24	1x3=3 (2 Groups)			**27**
	CHEST MEDICINE	CHM	18				**18**
	CARDIOLOGY	CRD	14				**14**
	PUBLIC HEALTH	PH	8				**8**
	PATHOPHYSIOLOGY	PP	7				**7**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	5				**5**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	4				**4**
	ENT DISEASES	ENT	4				**4**
	BIOISTATISTICS	BS	3				**3**
	THORACIC SURGERY	TS	3				**3**
	FAMILY MEDICINE	FM	4				**4**
	PEDIATRICS	PED	2				**2**
	MEDICAL GENETICS	MG	2				**2**
	EMERGENCY MEDICINE	EM	2				**2**
	IMMUNOLOGY	IMM	2				**2**
	RADIOLOGY	RAD	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		**128**	3		2	**133**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				2x2=4 (4 Groups)	**4**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			2x3=6 (4 Groups)		**6**
TOTAL			**128**	**3**	**6**	**6**	**143**
	INDEPENDENT LEARNING						**98**

Coordination Committee

HEAD	Ferda Özkan, MD, Prof.
SECRETARY	Banu Musaffa Salepçi, Assoc. Prof.
MEMBER	Müzeyyen Doğan, MD, Assoc. Prof.
MEMBER	Mustafa Aytek Şimşek, MD, Assist. Prof.
MEMBER	Emine Nur Özdamar, MD, Assist. Prof.

COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS
LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Asst. Prof.
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof.
CHEST MEDICINE	Emine Sevda Özdoğan, MD, Prof. Banu Musaffa Salepçi, MD, Assoc. Prof.
CARDIOLOGY	Muzaffer Değertekin, MD, Prof. Olcay Özveren, MD, Assoc. Prof. Kartal Emre Aslanger MD, Assoc. Prof. AyçaTürer Cabbar, MD, Assist. Prof. Mustafa Aytek Şimşek, MD, Assist. Prof. Burak Hünük ,MD, Assist. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyıkan, MD, Assist. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, MD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof.
EAR- NOSE -THROAT (ENT)	Yavuz Selim Pata, MD, Prof. Müzeyyen Doğan, MD, Assoc. Prof.
THORACIC SURGERY	Sina Ercan, MD, Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Prof.
PEDIATRICS	Hülya Sarıçoban, MD, Assoc. Prof. Fatma Tuba Coşkun, MD
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
RADIOLOGY	Ayşegül Görmez, MD.
EMERGENCY MEDICINE	Merve Ekşioğlu, MD. Mustafa Yazıcıoğlu, MD, Assist. Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Assist. Prof
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, Phd, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Banu Musaffa Salepçi, MD, Assoc. Prof. Olcay Özveren, MD, Assoc. Prof. Tuğhan Utku, MD, Assoc. Prof. Burak Hünük, MD, Assoc. Prof. Ayça Türer Cabbar, MD, Assist. Prof. Mustafa Aytek Şimşek, MD, Assist. Prof. Ferda Kartufan, MD, Assist. Prof. Seha Akduman, MD, Assist. Prof.

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of cardiovascular and respiratory systems,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. ***to convey*** necessary knowledge together **with performance measures** on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to cardiovascular and respiratory systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the level of primary health care service,**
7. ***to convey*** knowledge on principles of prescription,
8. ***to convey*** necessary knowledge on pharmacology of drugs effective on cardiovascular system,
9. ***to convey*** necessary knowledge on radiation physics and biology and its use in oncology,
10. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
11. ***to convey*** knowledge on principles of biostatistical analysis,
12. **to equip with basic and advanced clinical skills** (advanced cardiac life support-C2, approach to patient with cardiovascular clinical condition-C2) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0 ***recall*** anatomy, histology and physiology of cardiovascular and respiratory systems,

2.0 ***explain*** etiopathogenesis of clinical conditions (*upper respiratory tract problems, nasal obstruction, etc.-, infectious clinical conditions with upper and lower respiratory tract and lung involvement -pneumonia, tuberculosis, etc., circulatory lung disorders -pulmonary embolism, etc.-, obstructive/restrictive lung diseases, respiratory insuffiency, tobacco use, lung tumors,other lung diseases; diseases of coronary circulation and coronary arteries, diseases of cardiac valves, myocardial and pericardial diseases, blood stream infections and sepsis, cardiac problems in adults and children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases, nasal and paranasal sinus diseases, diseases of middle ear and eustachian tube, laryngeal diseases, voice disorders*) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

3.0 ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

4.0 ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,

5.0 ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

6.0 at multi-system level and/or related to cardiovascular and respiratory systems,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes, health care processes, clinical decision making process, clinical decisions and clinical practices

- which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (cardiovascular, pulmonary)

6.2. evaluation of emergency case (dyspnea)

6.3. approach to healthy individual or patient (cardiovascular disease, chest pain, cough and hemoptysis, dyspnea)

6.4. laboratory tests/examinations (cardiac markers-, coagulation tests-, blood gases-, pulmonary function tests)

6.5. imaging tests/examinations (radionuclide ventriculography, myocardial scintigraphy, cardiac PET, ventilation/perfusion scintigraphyi, PET in lung cancer)

6.6. point of care testing (urine strip/dipstick test)

6.7. making preliminary diagnosis or definitive diagnosis decision

6.8. making non-intervention or intervention decision

6.9. practicing non-intervention or intervention

6.10. referral/transport of healthy individual or patient

7.0 ***define*** radiation physics, biology and its use in oncology,

8.0 ***explain*** implementation of hypertension treatment guidelines,

9.0 ***explain*** pharmacology of drugs effective on cardiovascular system (autonomic system pharmacology, renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, anti-hypertension drugs, hypolipidemic drugs, antiarrhythmic drugs, antiplatelet, antithrombotic and thrombolytic drugs, drugs used in the treatment of asthma and chronic obstructive pulmonary disease, antitussive, expectorant and surfactant drugs),

10.0 explain genetics of cardiovascular and respiratory system,

11.0 ***explain*** ethical problems (rejection of treatment, organ transplantation, paternalism, reproductive and negative rights),

12.0 ***explain*** principles of biostatistical analysis,

13.0 ***perform*** basic clinical skills, practiced on phantom models (advanced cardiac life support), and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with cardiovascular clinical condition), required at primary health care service.

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
COMMITTEE ASSESSMENT MATRIX

PHASE III
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES
COURSE COMPONENT: COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
8.0.,9.0	PC	E. Genç E. N. Özdamar	17	8	8	33
1.0.,2.0	PT	F. Özkan A. Sav	17	7	7	31
1.0.,2.0.,5.0.,6.0-6.10	CHM	E. S. Özdoğan B. Salepçi	12	6	6	24
1.0.,2.0.,5.0.,6.0-6.10	CRD	M.Degertekin O. Özveren K. E Aslanger A. Cabbar B. Hünük M.A. Şimşek	11	4	4	19
3.0.,4.0	PH	R.E. Sezer H.A.Taşyıkan	6	2	2	10
2.0.,5.0	PP	M. Kaçar	5	2	2	9
2.0.,5.0.,6.0, 6,4	IDCM	M. Sönmezoğlu	3	2	2	7
11.0	BED	E. Vatanoğlu Lutz	3	1	1	5
1.0.,2.0.,5.0.,6.0	ENT	M. Doğan Y. Selim Pata	3	1	1	5
12.0	BS	Ç. Altunok	2	1	1	4
6.3	TS	S. Ercan	2	1	1	4
1.0.,2.0.,5.0.,6.0, 6.10	FM	G.Izbırak Ö. Tanrıöver	2	1	1	4
2.0.,5.0, 6.3	PED	H. Sarıçoban T. Coşkun	2	1	1	4
10.0	MG	A.Ç. Kuşkucu	2	1	1	4
6.2	EM	M. Ekşioğlu M. Yazıcıoğlu	1	1	1	3
2.0.,5.0	IMM	G.Y. Demirel	1	1	1	3
6.5	RAD	A. Görmez	1	0	0	1
TOTAL			**90**	**40**	**40**	**170**

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,5.0.,6.0-6.10	CHM	B. Salepçi	1	-	-	1
1.0.,2.0	PT	F. Özkan	2	-	-	2
8.0.,9.0	CRD	M. Değertekin	2	-	-	2
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
****41** out of 200 FE and ICE MCQs will be from Committee II (Each question is of worth **0.5** pts).

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK I / 23 - 27 Nov 2020

	Monday 23-Nov-2020	Tuesday 24-Nov-2020	Wednesday 25-Nov-2020	Thursday 26-Nov-2020	Friday 27-Nov-2020
09.00- 09.50	**Independent Learning**	**Lecture** General Signs and Principal Symptoms in Cardiovascular System Diseases K. E. Aslanger	Coronary Artery Disease I M. Değertekin	**ICP-CSL** (Advanced Cardiac Life Support) F. Kartufan / T. Utku	**Independent Learning**
10.00- 10.50	**Independent Learning**	**Lecture** Examination of the Heart K. E. Aslanger	**Lecture** Coronary Artery Disease II M. Değertekin	**Group A** Small Group Study SRPC / **Group B ICP** / **Group C IL** / **Group D IL**	**Independent Learning**
11.00- 11.50	**Independent Learning**	**Lecture** Hypertension M. A. Şimşek	**Lecture** Acetylcholinesterase Inhibitors E. Genç		**Independent Learning**
12.00- 12.50	**Independent Learning**	**Lecture** Pericardial Diseases M. A. Şimşek	**Lecture** Acetylcholine and Directly Acting Parasympathomimetic Drugs E. Genç	**Independent Learning**	**Independent Learning**
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Hypertension Treatment Guidelines E. N. Özdamar	**Lecture** Pathophysiology of Cardiovascular System Disorders I M. Kaçar	**Independent Learning**	**Lecture** Parasympatholitic Drugs E. Genç	**ICP-CSL** (Advanced Cardiac Life Support) F. Kartufan / T. Utku
15.00- 15.50	**Lecture** Anti-hypertensive Drugs I E. N. Özdamar	**Lecture** Pathophysiology of Cardiovascular System Disorders II M. Kaçar	**Independent Learning**	**Lecture** Sympathomimetic Drugs: Catecholamines & Noncatecholamines E. Genç	**Group A ICP** / **Group B** Small Group Study SRPC / **Group C IL** / **Group D IL**
16.00- 16.50	**Lecture** Anti-hypertensive Drugs II E. N. Özdamar	**Lecture** Pathophysiology of Cardiovascular System Disorders III M. Kaçar	**Independent Learning**	**Independent Learning**	
17.00-17.50	**Independent Learning**	**Lecture** Introduction to Autonomic System Pharmacology E. Genç	**Independent Learning**	**Independent Learning**	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK II / 30 Nov-4 Dec 2020

	Monday **30-Nov-2020**	**Tuesday** **1-Dec-2020**	**Wednesday** **2-Dec-2020**	**Thursday** **3-Dec-2020**	**Friday** **4-Dec-2020**
09.00- 09.50	**Lecture** Myocardium F. Özkan	**Lecture** Congestive Heart Failure I A. Türer Cabbar	**Lecture** Rheumatic Heart Disease A. Sav	**Independent Learning**	**Lecture** Pathophysiology of Respiratory System Disorders I M. Kaçar
10.00- 10.50	**Lecture** Ischemic Heart Disease I F. Özkan	**Lecture** Congestive Heart Failure II A. Türer Cabbar	**Lecture** CVS Tumors A. Sav	**Independent Learning**	**Lecture** Pathophysiology of Respiratory System Disorders II M. Kaçar
11.00- 11.50	**Lecture** Ischemic Heart Disease II F. Özkan	**Lecture** Grown-up Congenital Heart Disease A. Türer Cabbar	**Lecture** Hypersensitivity reactions G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Pathophysiology of Respiratory System Disorders III M. Kaçar
12.00- 12.50	**Lecture** Pharmacology of ReninAngiotensin System E. N. Özdamar	**Lecture** Pharmacology Case Studies E. N. Özdamar	**Lecture** Hypersensitivity reactions G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Pathophysiology of Respiratory System Disorders IV M. Kaçar
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathology of Endocardium & Heart Valves I A. Sav	**Lecture** History and Symptoms in Pulmonary Diseases E. S. Özdoğan	**Lecture** Electrocardiography I B. Hünük	**Lecture** Diagnostic Methods in Pulmonary Medicine S. Özdoğan	**Independent Learning**
15.00- 15.50	**Lecture** Pathology of Endocardium & Heart Valves II A. Sav	**Lecture** Physical Examination and Signs in Pulmonary Diseases E. S. Özdoğan	**Lecture** Electrocardiography II B. Hünük	**Lecture** Clinical Application of Pulmonary Function Tests S. Özdoğan	**Independent Learning**
16.00- 16.50	**Lecture** Valvular Heart Diseases O. Özveren	**Lecture** Chronic Obstructive Pulmonary Disease E. S. Özdoğan	**Lecture** Cardiac Arrhythmias B. Hünük	**Lecture** Bronchial Hyperreactivity and Asthma S. Özdoğan	**Independent Learning**
17.00-17.50	**Lecture** Infective Endocarditis and Acute Rheumatic Fever O. Özveren	**Lecture** Adrenergic Receptor Blockers E. Genç	**Lecture** Congenital Heart Disease in Pediatrics T. Çoşkun	**Lecture** Adrenergic Neuron Blockers E. Genç	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK III / 7-11 Dec 2020

	Monday 7-Dec-2020	Tuesday 8-Dec-2020	Wednesday 9-Dec-2020	Thursday 10-Dec-2020	Friday 11-Dec-2020
09.00- 09.50	**Lecture** Diseases of the Nose and Paranasal Sinuses Y. S. Pata	**Lecture** Pulmonary Tuberculosis S. Özdoğan	**Lecture** Pulmonary Infections I F. Özkan	**Lecture** Ethical Issues at the Beginning of Life E. Vatanoğlu Lutz	**ICP-CSL** (Advanced Cardiac Life Support) F. Kartufan / T. Utku
10.00- 10.50	**Lecture** Nasopharyngeal and Oropharyngeal Diseases Y. S. Pata	**Lecture** Pulmonary Embolism S. Özdoğan	**Lecture** Pulmonary Infections II F. Özkan	**Lecture** Ethical Issues in Paediatrics E. Vatanoğlu Lutz	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D Small Group Study** SRPC
11.00- 11.50	**Lecture** Atherosclerosis & Hypertension I A. Sav	**Lecture** Special Pulmonary Problems S. Özdoğan	**Lecture** Tracheobronchitis B. Salepçi	**Lecture** Ethics in Intensive Care E. Vatanoğlu Lutz	
12.00- 12.50	**Lecture** Atherosclerosis & Hypertension II A. Sav	**Lecture** Emergency Evaluation of Dyspnea M. Ekşioğlu	**Lecture** Pneumoniae B. Salepçi	**Lecture** Ethics in Psychiatry E. Vatanoğlu Lutz	**Independent Learning**
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Principals of Statistical Analysis I Ç. Altunok	**Lecture** Laryngeal and Voice Diseases M. Doğan	**Lecture** Chronic Obstructive Pulmonary Diseases F. Özkan	**Lecture** Pulmonary Hypertension B. Salepçi	**ICP-CSL** (Advanced Cardiac Life Support) F. Kartufan / T. Utku
15.00- 15.50	**Lecture** Principals of Statistical Analysis II Ç. Altunok	**Lecture** Diseases of the Middle Ear and Eustachian Tube M. Doğan	**Lecture** Asthma Bronchiale F. Özkan	**Lecture** Respiratory Failure B. Salepçi	**Group A IL** / **Group B IL** / **Group C Small Group Study** SRPC / **Group D ICP**
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Lecture** Congenital Lung Anomalies & Atalectasis F. Özkan	**Lecture** Drugs Used in Cardiac Arrythmias I E. N. Özdamar	
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Pathology of Upper Respiratory Tract F. Özkan	**Lecture** Drugs Used in Cardiac Arrythmias II E. N. Özdamar	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK IV / 14-18 Dec 2020

	Monday 14-Dec-2020	Tuesday 15-Dec-2020	Wednesday 16-Dec-2020	Thursday 17-Dec-2020	Friday 18-Dec-2020
09.00- 09.50	**Independent Learning**	**Independent Learning**	**Lecture** Tumors of the Respiratory System I A. Sav	**Lecture** Diuretic Agents I E. N. Özdamar	**Independent Learning**
10.00- 10.50	**Independent Learning**	**Independent Learning**	**Lecture** Tumors of the Respiratory System II A. Sav	**Lecture** Diuretic Agents II E. N. Özdamar	**Independent Learning**
11.00- 11.50	**Independent Learning**	**Lecture** Drugs Used in the Treatment of Dyslipidemias I E. N. Özdamar	**Lecture** Congestive Heart Failure F. Özkan	**Lecture** Drugs Used in the Treatment of Angina Pectoris E. N. Özdamar	**Independent Learning**
12.00- 12.50	**Independent Learning**	**Lecture** Drugs Used in the Treatment of Dyslipidemias II E. N. Özdamar	**Lecture** Congestive Heart Failure & Pericardium F. Özkan	**Lecture** Anticoagulant, Antiplatelet & Thrombolytic drugs E. N. Özdamar	**Independent Learning**
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (Examination of Cardiovascular and Respiratory System) O. Özveren / M. A. Şimşek / B. Salepçi / S. Akduman / A. Türer/ B. Hünük	**ICP-CSL** (Examination of Cardiovascular and Respiratory System) O. Özveren / M. A. Şimşek / B. Salepçi / S. Akduman / A. Türer/ B. Hünük	**Lecture** Approach to the Patient with Cough and Heameoptysis in Primary Care Ö. Tanrıöver	**Lecture** Pathology of Pleural and Mediastinal Diseases A. Sav	**Pathology Laboratory** (Cardiovascular and Respiratory Systems) F. Özkan / A. Sav **Group B** **Group A IL**
15.00- 15.50	**Group C ICP** **Group D Small Group Study** SRPC **Group A IL** **Group B IL**	**Group C Small Group Study** SRPC **Group D ICP** **Group A IL** **Group B IL**	**Lecture** Approach to the Patient with Dyspnea in Primary Care Ö. Tanrıöver	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases I R.E. Sezer	
16.00- 16.50			**Lecture** Pediatric Advanced Life Support M. Yazıcıoğlu	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases II R.E. Sezer	**Group B IL** **Group A**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases III R.E. Sezer	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK V / 21-25 Dec 2020

	Monday 21-Dec-2020	Tuesday 22-Dec-2020	Wednesday 23-Dec-2020	Thursday 24-Dec-2020	Friday 25-Dec-2020
09.00- 09.50	**Independent Learning**	**Lecture** Bloodstream Invasion & Sepsis I M. Sönmezoğlu	**ICP-CSL** (Examination of Cardiovascular and Respiratory System) O. Özveren / M. A. Şimşek / B. Salepçi / S. Akduman / A. Türer/ B. Hünük	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Respiratory Muscles and Surgical Anatomy of Thorax S. Ercan	**Lecture** Bloodstream Invasion & Sepsis II M. Sönmezoğlu	**Group C IL** / **Group D IL** / **Group B ICP** / **Group A Small Group Study** SRPC	**Independent Learning**	**Independent Learning**
11.00- 11.50	**Lecture** Surgical Disorders of Mediastinum and the Diaphragm S. Ercan	**Lecture** Cardiac Infections M. Sönmezoğlu		**Independent Learning**	**Independent Learning**
12.00- 12.50	**Lecture** Surgical Treatment of Pulmonary Diseases S. Ercan	**Lecture** Approach to Patient with Chest Pain in Primary Care I G. İzbırak	**Independent Learning**	**Independent Learning**	**Independent Learning**
12.50- 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Preparing to Analyse Data Ç. Altunok	**Lecture** Approach to Patient with Chest Pain in Primary Care II G. İzbırak	**Lecture** Pharmacology and Toxicology of Tobacco E. N. Özdamar	**Independent Learning**	**ICP-CSL** (Examination of Cardiovascular and Respiratory System) O. Özveren / M. A. Şimşek / B. Salepçi / S. Akduman / A. Türer/ B. Hünük
15.00- 15.50	**Independent Learning**	**Lecture** Treatment of Cough & Drugs Used in the Treatment of Common Cold E. N. Özdamar	**Lecture** Drugs Used in the Treatment of Asthma & Chronic Obstructive Lung Disease E. N. Özdamar	**Independent Learning**	**Group C IL** / **Group D IL** / **Group B Small Group Study** SRPC / **Group A ICP**
16.00- 16.50	**Independent Learning**	**Lecture** Drugs Used in Congestive Heart Disease I E. N. Özdamar	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases IV R.E. Sezer	**Independent Learning**	
17.00-17.50	**Independent Learning**	**Lecture** Drugs Used in Congestive Heart Disease II E. N. Özdamar	**Lecture** Epidemiology, Prevention and Control of Chronic Non-Communicable Respiratory Diseases R. E. Sezer	**Independent Learning**	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK VI / 28 Dec 2020-1 Jan 2021

	Monday 28-Dec-2020	Tuesday 29-Dec-2020	Wednesday 30-Dec-2020	Thursday 31-Dec-2020	Friday 1-Jan-2021
09.00- 09.50	**Lecture** Bronchiectasis B. Salepçi	**Lecture** Upper and Lower Respiratory System Infections I Lecturer	**Lecture** Interstitial Lung Diseases B. Salepçi	**Independent Learning**	**New Year's Day**
10.00- 10.50	**Lecture** Lung Cancer B. Salepçi	**Lecture** Upper and Lower Respiratory System Infections II Lecturer	**Lecture** Sleep Apnea Syndrome B. Salepçi	**Independent Learning**	
11.00- 11.50	**Lecture** Pleural Diseases B. Salepçi	**Lecture** Inherited Respiratory System Disorders A. Kuşkucu	**Multidisciplinary Case Discussion Panel**	**Independent Learning**	
12.00- 12.50	**Lecture** X-Ray Examination of the Lungs A. Görmez	**Lecture** Inherited Cardiovascular Disorders A.Ç. Kuşkucu	**Multidisciplinary Case Discussion Panel**	**Independent Learning**	
12.50- 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Approach to the Pediatric Patient with Pneumonia H. Sarıçoban	**Independent Learning**	**Lecture** Chronic Restrictive Pulmonary Diseases I A. Sav	**Independent Learning**	**New Year's Day**
15.00- 15.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases I H.A.Taşyıkan	**Independent Learning**	Chronic Restrictive Pulmonary Diseases II A. Sav	**Independent Learning**	
16.00- 16.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases II H.A.Taşyıkan	**Independent Learning**	**Lecture** Congenital Heart Disease I A. Sav	**Independent Learning**	
17.00-17.50	**Lecture** Public Health and Chronic Non-Communicable Diseases H.A. Taşyıkan	**Independent Learning**	**Lecture** Congenital Heart Disease II A. Sav	**Independent Learning**	

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK VII / 4-8 Jan 2021

	Monday 4-Jan-2021	Tuesday 5-Jan-2021	Wednesday 6-Jan-2021	Thursday 7-Jan-2021	Friday 8-Jan-2021
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
13.00- 14.00	LUNCH BREAK				Program Evaluation Session Committee II Coordination Committee Members
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

COMMITTEE III - GASTROINTESTINAL SYSTEM

DISTRIBUTION of LECTURE HOURS

January 11, 2021 - February 19, 2021

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	GASTROENTEROHEPATOLOGY	GE	24				**24**
	PATHOLOGY	PT	14		1x3=3 (2 Groups)		**17**
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	10				**10**
	PHARMACOLOGY	PC	5				**5**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	4				**4**
	PUBLIC HEALTH	PH	3				**3**
	PHYTOTHERAPY	PHY	3				**3**
	BIOSTATISTICS	BS	3				**3**
	IMMUNOLOGY	IMM	2				**2**
	PATHOPHYSIOLOGY	PP	2				**2**
	FAMILY MEDICINE	FM	2				**2**
	MEDICAL GENETICS	MG	2				**2**
	EMERGENCY MEDICINE	EM	2				**2**
	RADIOLOGY	RAD	1				**1**
	PEDIATRICS	PED	1				**1**
	PEDIATRIC SURGERY	PEDS	1				**1**
	GENERAL SURGERY	GS	1				**1**
	INTERDISCIPLINARY	MCDP				2	2
	TOTAL		80		3	2	85
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				1X2=2 (4 Groups)	**2**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			1X3=3 (4 Groups)		**3**
TOTAL			**80**		**6**	**4**	**90**
	INDEPENDENT LEARNING						**45**

Coordination Committee

HEAD	Meltem Ergün, MD, Assoc. Prof.
SECRETARY	Barış Murat Ayvacı, MD, Assist. Prof.
MEMBER	Ferda Özkan, MD, Prof.
MEMBER	Şafak Karaçay, MD, Assoc. Prof.
MEMBER	Emine Nur Özdamar, MD, Assist. Prof.

COMMITTEE III - GASTROINTESTINAL SYSTEM
LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
GASTROENTEROHEPATOLOGY	Cengiz Pata, MD, Prof. Meltem Ergün, MD, Assoc. Prof. Arzu Yalçın, MD
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof. Ezgi Hacıhasanoğlu, MD
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, MD, Assoc. Prof.
INFECTIOUS DISEASES AND MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof. M. Engin CELEP, PhD, Assist. Prof
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Prof.
BIOISTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Assoc. Prof. Emin Gökhan Gencer, MD, Assist. Prof.
PEDIATRICS	Meltem Uğraş, MD, Prof.
PEDIATRIC SURGERY	Şafak Karaçay, MD, Assoc.Prof.
GENERAL SURGERY	Gürkan Tellioğlu, MD, Prof.
RADIOLOGY	Ayşegül Görmez, MD.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Özlem Tanrıöver, MD, Prof. Güldal İzbırak, MD, Assoc. Prof. Serdar Özdemir, MD, Assist. Prof. Mirkhalig Javadov, MD, Assist. Prof. Fırat Demircan, MD, Assist. Prof. Utku Göktuğ, MD, Assist. Prof.

COMMITTEE III - GASTROINTESTINAL SYSTEM

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of gastrointestinal system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
8. ***to convey*** knowledge on phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
9. ***to convey*** knowledge on biostatistical analysis of association between variables,
10. ***to convey*** necessary knowledge on legal regulations and ethical principles for end-of-life decisions,
11. ***to equip with*** basic and advanced clinical skills (approach to patient with gastrointestinal clinical condition-C4) required at primary health care service level.
12. ***to convey*** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy,

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0 ***recall*** anatomy, histology and physiology of gastrointestinal system,

2.0 ***explain*** etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

3.0 ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

4.0 ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,

5.0 ***explain*** importance of healthy nutrition, principles of balanced diet, and measurement of nutritional status,

6.0 ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

7.0 at multi-system level and/or related to gastrointestinal system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

7.1. practice of history taking and physical examination (gastrointestinal)
7.2. evaluation of emergency case (acute abdominal pain)
7.3. approach to healthy individual or patient (diarrhea)
7.4. laboratory tests/examinations
7.5. imaging tests/examinations (scintigraphy of liver/spleen, PET in gastrointestinal system tumors)
7.6. point of care testing
7.7. making preliminary diagnosis or definitive diagnosis decision
7.8. making non-intervention or intervention decision
7.9. practicing non-intervention or intervention
7.10. referral/transport of healthy individual or patient

8.0 ***list*** differences of gastrointestinal clinical conditions that may occur in children,

9.0 ***explain*** liver transplantation (indications, contraindications, conditions, risks, methods, patient care, results and monitorization),

10.0 ***explain*** pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic agents, laxatives) that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,

11.0 ***explain*** genetics of gastrointestinal system,

12.0 ***explain*** phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,

13.0 ***define*** biostatistical analysis of association between variables,

14.0 ***tell*** legal regulations and ethical principles for end-of-life decisions,

15.0 ***perform*** basic clinical skills, practiced on phantom models and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with gastrointestinal clinical condition), required at primary health care service.

16.0 ***to convey*** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy.

COMMITTEE III - GASTROINTESTINAL SYSTEM
COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MED 302 INTRODUCTION to CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE III - GASTROINTESTINAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**DISCIPLINE**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0.,2.0.,3.0.,4.0.,6.0.,7.0-7.10	GE	C. Pata M. Ergün	27	7	7	**41**
2.0.,6.0.,7.4	PT	F. Özkan	17	4	4	**25**
14.0	BED	E. Vatanoğlu	11	3	3	**17**
10.0	PC	E. Genç E. N. Özdamar	6	2	2	**10**
2.0.,3.0.,4.0.,6.0.,7.0, 7.4	IDCM	M. Sönmezoğlu	6	1	1	**8**
3.0.,4.0.,5.0	PH	R.E. Sezer H.A.Taşyıkan	3	1	1	**5**
12.0, 16.0	PHR (PHY)	E. Yeşilada	3	1	1	**5**
13.0	BS	Ç. Altunok	3	1	1	**5**
2.0.,6.0	IMM	G. Y. Demirel	2	1	1	**4**
2.0.,6.0	PP	M. Kaçar	2	1	1	**4**
7.2, 7.3, 7.10	FM	G. İzbırak Ö. Tanrıöver	2	1	1	**4**
11.0	MG	A.Ç. Kuşkucu	2	1	1	**4**
2.0.,3.0.,4.0.,6.0.,7.2	EM	S. Sarıkaya E. G. Gencer	2	0	0	**2**
7.5	RAD	A. Görmez	1	0	0	**1**
5.0, 8.0	PED	M. Uğraş	1	0	0	**1**
1.0.,2.0.,3.0.,4.0.,6.0.,7.0	PEDS	Ş. Karaçay	1	0	0	**1**
9.0	GS	G. Tellioğlu	1	0	0	**1**
		TOTAL	**90**	**24**	**24**	**138**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (EMQ)**			
			CE	**FE**	**IE**	**Total**
1.0.,2.0.,3.0.,4.0.,6.0.,7.0	GE	M. Ergün	3	-	-	3
2.0.,6.0.,7.4	PT	F. Özkan	2	-	-	2
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:** Points
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
****23** out of 200 FE and ICE MCQs will be from Committee III (Each question is of worth **0.5** pts).

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK I / 11-15 Jan 2021

	Monday 11-Jan-2021	Tuesday 12-Jan-2021	Wednesday 13-Jan-2021	Thursday 14-Jan-2021	Friday 15-Jan-2021
09.00- 09.50	**Lecture** Palliative Care Ethics E. Vatanoğlu Lutz	**Lecture** Ethics of Dealing with Addiction E. Vatanoğlu Lutz	**Lecture** Semiology I A. Yalçın	**Lecture** Complex Diseases-Inherited Gastrointestinal System Disorders A.Ç. Kuşkucu	**Lecture** Functional GI Disorders & Irritable Bowel Disease C. Pata
10.00- 10.50	**Lecture** Medical Ethical Decision-Making E. Vatanoğlu Lutz	**Lecture** Ethics of Elective Interventions E. Vatanoğlu Lutz	**Lecture** Semiology II A. Yalçın	**Lecture** Complex Diseases-Inherited Gastrointestinal System Disorders A.Ç. Kuşkucu	**Lecture** Comparing Groups-categorical Data Ç. Altunok
11.00- 11.50	**Lecture** Ethics and the Law E. Vatanoğlu Lutz	**Lecture** The Ethics of Testing and Screening E. Vatanoğlu Lutz	**Lecture** Steatohepatitis A. Yalçın	**Lecture** Radiology of Gastrointestinal System A. Görmez	**Lecture** Comparing Groups-countinous Data I Ç. Altunok
12.00- 12.50	**Lecture** Public Health Ethics E. Vatanoğlu Lutz	**Lecture** The Ethics of Dealing with Infectious Diseases E. Vatanoğlu Lutz	**Lecture** Alcoholic Liver Disease A. Yalçın	**Lecture** Approach to the Patient with Abdominal Pain Regarding to Primary Care G. İzbırak	**Lecture** Comparing Groups-countinous Data II Ç. Altunok
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** The Ethics of Patents on Life E. Vatanoğlu Lutz	**Lecture** Ethical Issues at the End of Life E. Vatanoğlu Lutz	**Lecture** Abdominal Pain M. Ergün	**Lecture** Inflammatory Bowel Disease M. Ergün	**Lecture** Acute Gastroenteritis M. Sönmezoğlu
15.00- 15.50	**Lecture** Agents used in the Treatment of Peptic Ulcer I E. Genç	**Independent Learning**	**Lecture** Disease of the Bile Duct and Gall Bladder M. Ergün	**Lecture** Premalignant Lesion of the Colon M. Ergün	**Lecture** Hepatitis I M. Sönmezoğlu
16.00- 16.50	**Lecture** Agents used in the Treatment of Peptic Ulcer II E. Genç	**Lecture** Immunologic Tolerance and Autoimmunity G. Yanıkkaya Demirel	**Lecture** Acute and Chronic Pancreatitis M. Ergün	**Lecture** Pathophysiology of Gastrointestinal Disorders I M. Kaçar	**Lecture** Hepatitis II M. Sönmezoğlu
17.00-17.50	**Lecture** Clinical Approach to the Patient with Acute Abdominal Pain F.Çelikmen	**Lecture** Immunologic Tolerance and Autoimmunity G. Yanıkkaya Demirel	**Lecture** Gastrointestinal Bleedings in Children Ş. Karaçay	**Lecture** Food Poisoning M. Sönmezoğlu	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE III - GASTROINTESTINAL SYSTEM

WEEK II / 18-22 Jan 2021

	Monday 18-Jan-2021	Tuesday 19-Jan-2021	Wednesday 20-Jan-2021	Thursday 21-Jan-2021	Friday 22-Jan-2021
09.00- 09.50	**Lecture** Public Health and Nutrition I R.E. Sezer	**Lecture** Oral Pathology F. Özkan	**Lecture** Gastritis and Helicobacter Pylori C. Pata	**Lecture** Pathology of Stomach I F. Özkan	**Lecture** Digestive & Antidiarrheal Drugs E. N. Özdamar
10.00- 10.50	**Lecture** Public Health and Nutrition II R.E. Sezer	**Lecture** Pathology of Esophagus I F. Özkan	**Lecture** Gastroeusophegeal Reflux (GE) and Esophageal Motility Disorder C. Pata	**Lecture** Pathology of Stomach II F. Özkan	**Lecture** Transplantation of liver G. Tellioğlu
11.00- 11.50	**Lecture** Acute Liver Failure M. Ergün	**Lecture** Pathology of Esophagus II F. Özkan	**Lecture** Tumors of Eusophagus, Stomach and Small Intestine C. Pata	**Lecture** Pathophysiology of Gastro–intestinal Disorders II M. Kaçar	**Lecture** Pathology of Liver I E. Hacıhasanoğlu
12.00- 12.50	**Lecture** Autoimmune Hepatitis M. Ergün	**Lecture** Approach to the Patient with Abdominal Pain Regarding to Primary Care G. İzbırak	**Lecture** Cirrhosis and Portal Hypertension M. Ergün	**Lecture** Pathophysiology of Gastro–intestinal Disorders III M. Kaçar	**Lecture** Pathology of Liver II E. Hacıhasanoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Wilson Disease and Hemochromatisis M. Ergün	**ICP-CSL** Physical Examination of Gastrointestinal System) M. Javadov	**Lecture** Phytotherapy-IV E. Celep	**Lecture** Toxic Hepatitis M. Ergün	**ICP-CSL** Physical Examination of Gastrointestinal System) U. Göktuğ
15.00- 15.50	**Lecture** Mass Lesions of the Liver M. Ergün	**Group D** Small Group Study SRPC / **Group C** ICP / **Group A** IL / **Group B** IL	**Lecture** Phytotherapy-V E. Celep	**Lecture** Tumors of the Bile Ducts and Pancreas M. Ergün	**Group C** IL / **Group D** IL / **Group A** Small Group Study SRPC / **Group B**
16.00- 16.50	**Independent Learning**		**Lecture** Phytotherapy-VI E. Celep	**Independent Learning**	
17.00-17.50	**Lecture** Mesenteric Ischemia E. G. Gencer	**Independent Learning**	**Lecture** Pathology of Appendix & Peritoneum E. Hacıhasanoğlu	**Independent Learning**	**Independent Learning**

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK III / 25 – 29 Jan 2021

<table>
<tr><th></th><th colspan="3">Monday
25-Jan-2021</th><th>Tuesday
26-Jan-2021</th><th colspan="5">Wednesday
27-Jan-2021</th><th colspan="4">Thursday
28-Jan-2021</th><th>Friday
29-Jan-2021</th></tr>
<tr><td>09.00- 09.50</td><td colspan="3">Lecture
Pathology of Liver & Biliary System I
E. Hacıhasanoğlu</td><td>Lecture
Antiemetic Agents
E. N. Özdamar</td><td colspan="5">Lecture
Pathology of Intestinal Diseases I
F. Özkan</td><td colspan="4">Independent learning</td><td>Independent learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="3">Lecture
Pathology of Liver & Biliary System II
E. Hacıhasanoğlu</td><td>Lecture
Clinical Nutrition
M. Uğraş</td><td colspan="5">Lectureo
Pathology of Intestinal Diseases II
F. Özkan</td><td colspan="4" rowspan="2">ICP-CSL
History Taking
S. Özdemir / G. İzbırak/
Ö. Tanrıöver
Group C ICP</td><td rowspan="2">ICP-CSL
History Taking
S. Özdemir / G. İzbırak/
Ö. Tanrıöver
Group B ICP</td></tr>
<tr><td>11.00- 11.50</td><td colspan="3">Lecture
Pathology of Liver & Biliary System III
E. Hacıhasanoğlu</td><td>Lecture
Jaundice
C. Pata</td><td colspan="5">Lecture
Malabsorbtion
M. Ergün</td></tr>
<tr><td>12.00- 12.50</td><td colspan="3">Lecture
Pathology of Liver & Biliary System IV
E. Hacıhasanoğlu</td><td>Lecture
Chronic Viral Hepatitis
C. Pata</td><td colspan="5">Lecture
Peptic Ulcer Disease
M. Ergün</td><td colspan="4">Lecture
Approach to the Patient with Diarrhea Regarding to Primary Care
Ö. Tanrıöver</td><td>Independent Learning</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="15">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="3">Pathology Laboratory
(Gastrointestinal System)
F. Özkan/ A. Sav</td><td rowspan="2">Group B</td><td rowspan="2">Group A IL</td><td>Multidisciplinary Case Discussion Panel</td><td colspan="5">ICP-CSL
(History Taking and Physical Examination of Gastrointestinal System)
F. Demircan/ S. Özdemir /
G. İzbırak/ Ö. Tanrıöver</td><td colspan="4">ICP-CSL
(History Taking and Physical Examination of Gastrointestinal System)
F. Demircan/ S. Özdemir /
G. İzbırak/ Ö. Tanrıöver</td><td>Lecture
Laxatives
E. N. Özdamar</td></tr>
<tr><td>15.00- 15.50</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="2">Group A ICP</td><td rowspan="2">Group B Small Group Study SRPC</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group D ICP</td><td rowspan="2">Group C Small Group Study SRPC</td><td>Independent Learning</td></tr>
<tr><td>16.00- 16.50</td><td>Group B IL</td><td>Group A</td><td>Lecture
Epidemiology, Prevention and Control of Obesity
H. A. Taşyıkan</td><td>Independent Learning</td></tr>
<tr><td>17.00-17.50</td><td colspan="3">Independent Learning</td><td>Independent Learning</td><td colspan="3">Independent Learning</td><td colspan="2">Independent Learning</td><td>IL</td><td>Independent Learning</td></tr>
</table>

MIDTERM BREAK

1-14 FEBRUARY 2021

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK IV / 15- 19 Feb 2021

<table>
<tr><th></th><th>Monday
15-Feb-2021</th><th>Tuesday
16-Feb-2021</th><th>Wednesday
17-Feb-2021</th><th>Thursday
18-Feb-2021</th><th colspan="2">Friday
19-Feb-2021</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td colspan="2">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="2" rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td colspan="4">LUNCH BREAK</td><td colspan="2">Program Evaluation Session
Committee III
Coordination Committee
Members</td></tr>
<tr><td>12.50 – 14.00</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="2">ELECTIVE COURSE WEEK I</td><td rowspan="2">Independent Learning</td></tr>
<tr><td>14.00- 14.50</td></tr>
<tr><td>15.00 -15.50</td><td rowspan="2">Independent Learning</td><td rowspan="2">ELECTIVE COURSE WEEK I</td></tr>
<tr><td>16.00 - 16.50</td></tr>
<tr><td>17.00 - 17.50</td><td colspan="2">Independent Learning</td></tr>
</table>

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

DISTRIBUTION of LECTURE HOURS

February 22, 2021 – April 09, 2021

COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PATHOLOGY	PT	32		1x2=2 (2 Groups)		**34**
	OBST & GYNEC	OBS-GYN	16				**16**
	ENDOCRINOLOGY	END	15				**15**
	NEPHROLOGY	NE	15				**15**
	PHARMACOLOGY	PC	14				**14**
	INFECTIOUS DISEASES	ID	5				**5**
	MEDICAL MICROBIOLOGY	MM	0		2x1=2 (4 Groups)		**2**
	PATHOPHYSIOLOGY	PP	7				**7**
	MEDICAL GENETICS	MG	6				**6**
	PEDIATRICS	PED	2				**2**
	PEDIATRIC ENDOCRINOLOGY	PED END	4				**4**
	UROLOGY	URO	6				**6**
	FAMILY MEDICINE	FM	4				**4**
	PUBLIC HEALTH	PH	4				**4**
	BIOSTATISTICS	BS	3				**3**
	IMMUNOLOGY	IM	2				**2**
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	2				**2**
	PHYTOTHERAPY	PHR	2				**2**
	RADIOLOGY	RAD	2				**2**
	EMERGENCY MEDICINE	EM	1				**1**
	PEDIATRIC SURGERY	PED-S	1				**1**
	HISTOLOGY	HST	1				**1**
	GENERAL SURGERY	GS	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		145		4	2	**151**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				2x2=4 (4 Groups)	**4**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			1x3=3 (4 Groups) 1x2=2 (4 Groups) 1x3=3 (4 Groups)		**8**
TOTAL			**145**		**12**	**6**	**163**
	INDEPENDENT LEARNING						**101**

Coordination Committee

HEAD	Hasan Aydın, MD, Prof.
SECRETARY	Oya Alagöz, MD, Assist. Prof.
MEMBER	Gülçin Kantarcı, MD, Prof.
MEMBER	Rukset Attar, MD, Prof.
MEMBER	Erdem Söztutar, MD, Assist. Prof.

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof. Ezgi Hacıhasanoğlu, MD
OBSTETRICS and GYNECOLOGY	Orhan Ünal, MD, Prof. Rukset Attar, MD, Prof. Gazi Yıldırım, MD, Prof. Erkut Attar, MD Prof. Tanju Demirören, MD
ENDOCRINOLOGY	Hasan Aydın, MD, Prof. Fahrettin Keleştemur, MD, Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD Prof.
MEDICAL MICROBIOLOGY	İ. Çağatay Acuner, MD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
BIOMEDICAL ETHICS&DEONTOLOGY	Elif Vatanoğlu Lutz, MD, PhD, Assoc. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyıkan, MD, Assist. Prof.
FAMILY MEDICINE	Özlem Tanrıöver, MD, Prof. Ayşe Arzu Akalın, MD, Assist. Prof.
PEDIATRICS	Mustafa Berber, MD, Assist. Prof. Fatma Tuba Coşkun, MD Çiğdem Ayanoğlu, MD.
PEDIATRIC ENDOCRINOLOGY	Belma Haliloğlu, MD, Assoc. Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
RADIOLOGY	Özgür Sarıca, MD.
PHYTOTHERAPY	M. Engin Celep, PhD, Assist. Prof.
HISTOLOGY & EMBRYOLOGY	Oya Akçın Alagöz, MD, Assist. Prof.
NEPHROLOGY	Gülçin Kantarcı, MD, Prof.
UROLOGY	Murat Kuru, MD. Assist. Prof.
PEDIATRIC SURGERY	Şafak Karaçay, MD, Assoc. Prof.
GENERAL SURGERY	Gürkan Tellioğlu, MD, Prof.
EMERGENCY MEDICINE	Emin Gökhan Gencer, MD, Assist. Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Rukset Attar, MD, Prof. Gazi Yıldırım, MD, Prof. Özlem Tanrıöver, MD, Prof. Ayşe Arzu Akalın, MD, Assist. Prof. Mustafa Berber, MD, Assist. Prof. Çiğdem Ayanoğlu, MD.

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

AIMS and LEARNING OBJECTIVES

ENDOCRINE & REPRODUCTIVE SYSTEMS

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2. ***to convey*** knowledge on health care service practices related to reproductive care,
3. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
4. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
5. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
6. ***to convey*** knowledge on mechanism of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
7. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision-making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
8. ***to convey*** knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
9. ***to convey*** knowledge on genetics of endocrine and reproductive systems,
10. ***to convey*** knowledge on phytotherapeutic agents that are effective on endocrine system or on clinical conditions involving endocrine system,
11. ***to convey*** knowledge on design and biostatistical analysis of survival research,
12. ***to convey*** knowledge on legal regulations and ethical principles related to reproductive care,
13. ***to equip with*** basic and advanced clinical skills (*normal spontaneous vaginal delivery on phantom model-C5*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0 ***recall*** anatomy, embryology, histology and physiology of endocrine and reproductive systems,

2.0 ***explain*** physiology of normal spontaneous vaginal delivery,

3.0 ***define*** practice of reproductive care,

4.0 ***explain*** etiopathogenesis of clinical conditions (menstrual cycle/developmental conditions/congenital and sexually transmitted infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

5.0 ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

6.0 ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,

7.0 ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

8.0 at multi-system level and/or related to endocrine and reproductive systems,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

8.1. practice of history taking and physical examination (gynecological, breast)

8.2. evaluation of emergency case

8.3. approach to healthy individual or patient (pregnancy)

8.4. laboratory tests/examinations (venous blood collection, throat swab specimen, sputum sample collection, thyroid function tests, diabetes tests, rapid screening [antigen/antibody] tests, throat culture, sputum culture)

8.5. imaging tests/examinations (radiological examinations in gynecology, breast imaging, radioisotope imaging of thyroid and parathyroid)

8.6. point of care testing (diabetes tests, rapid screening [antigen/antibody] tests)

8.7. making preliminary diagnosis or definitive diagnosis decision

8.8. making non-intervention or intervention decision

8.9. practicing non-intervention or intervention

8.10. referral/transport of healthy individual or patient

9.0 ***explain*** pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs, insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,

10.0 ***explain*** genetics of endocrine and reproductive systems,

11.0 ***explain*** mechanisms of action for phytotherapeutic agents that are effective on endocrine system or in clinical conditions related to endocrine system,

12.0 ***define*** design and biostatistical analysis of survival research,

13.0 ***explain*** legal regulations and ethical principles related to reproductive care,

14.0 ***perform*** basic clinical skills, practiced on phantom models (normal spontaneous vaginal delivery), and advanced clinical skills, practiced on simulated/standardized patients required at primary health care service.

URINARY SYSTEM

AIMS

In evidence-based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of urinary system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. ***to convey*** knowledge on mechanism of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to urinary system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the** level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. ***to convey*** knowledge on genetics of urinary system,
9. ***to convey*** knowledge on phytotherapeutic agents that are effective on urinary system or on clinical conditions involving urinary system,
10. ***to convey*** knowledge on use of biostatistical software and presentation of results,
11. ***to convey*** knowledge on legal regulations and ethical principles related to reproductive care,
12. ***to equip with*** basic and advanced clinical skills *(gynecological examination, "Pap-smear" collection, intrauterine device placement, breast examination, physical examination in neonate, infant and prepubertal/pubertal child)* required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

U1.0. ***recall*** anatomy, histology and physiology of urinary system,

U2.0. ***explain*** etiopathogenesis of clinical conditions (renal hemodynamics, acid-base equilibrium, renal clinical conditions, urinary system stones, urinary system infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,

U3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

U4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,

U5.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,

U6.0. at multi-system level and/or related to urinary system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision-making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

U6.1. practice of history taking and physical examination (neonatal, prepubertal/pubertal)

U6.2. evaluation of emergency case (urological emergencies)

U6.3. approach to healthy individual or patient (urethral-vaginal-cervical discharge/swab specimen, fecal specimen collection)

U6.4. laboratory tests/examinations (urethral-vaginal-cervical discharge culture, fecal culture)

U6.5. imaging tests/examinations (uroradiology, renal scintigraphy (GFR, ERPF, Renogram))

U6.6. point of care testing

U6.7. making preliminary diagnosis or definitive diagnosis decision

U6.8. making non-intervention or intervention decision

U6.9. practicing non-intervention or intervention

U6.10. referral/transport of healthy individual or patient

U7.0. ***explain*** pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,

U8.0. ***explain*** pharmacology of androgens and anabolic steroids, and drugs that affect bone mineral homeostasis,

U9.0. ***explain*** genetics of urinary system,

U10.0. ***explain*** mechanisms of action for action for phytotherapeutic agents that are effective on urinary system or in clinical conditions related to urinary system,

U11.0. ***define*** use of biostatistical software and presentation of results,

U12.0. ***perform*** basic clinical skills, practiced on phantom models, and advanced clinical skills, practiced on simulated/standardized patients (gynecological examination, “Pap-smear” collection, intrauterine device placement, breast examination, physical examination in neonate, infant and prepubertal/pubertal child), required at primary health care service.

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS
COMMITTEE ASSESSMENT MATRIX

PHASE III
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES
COURSE COMPONENT: COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0, 4.0, 7.0, 8.4, U1, U2, U6.4	PT	F. Özkan A. Sav	**22**	10	10	**40**
1.0-8.10	OBS-GYN	O. Ünal R. Attar G. Yıldırım T. Demirören E. Attar	**12**	5	5	**20**
1.0, 4 - 8.10	END	H. Aydın F. Keleştemur	**11**	5	5	**19**
U1.0 - U6.0	NE	G. Kantarcı	**11**	5	5	**19**
9.0 , U7.0, U8.0	PC	E. Genç E. N. Özdamar	**9**	4	4	**17**
4.0 - 8.0, 8.4, U5, U6.0, U6.4	IDCM	M. Sönmezoğlu	**3**	2	2	**7**
4.0, 7.0, U2.0, U5.0	PP	M. Kaçar	**4**	2	2	**8**
10.0, U9.0	MG	A. Ç. Kuşkucu	**4**	2	2	**8**
1.0, 4.0-8.0, U6.1	PED	M. Berber F.T. Coşkun Ç. Ayanoğlu	**2**	1	1	**4**
1.0, 4.0-8.0, U6.1	PED END	B. Haliloğlu	**2**	1	1	**4**
U1.0.-U6.10	URO	M. Kuru	**6**	2	2	**8**
6.0, 8.0,8.1, 8.3, 8.10, U2.0	FM	A.A. Akalın Ö. Tanrıöver	**2**	2	2	**6**
5.0, 6.0, U3.0, U4.0	PH	R.E. Sezer H.A. Taşyıkan	**2**	1	1	**4**
12.0, U11.0	BS	Ç. Altunok	**2**	1	1	**4**
4.0, 7.0, U2.0, U5.0	IMM	G. Y. Demirel	**1**	1	1	**3**
13.0	BED	E. Vatanoğlu Lutz	**1**	1	1	**3**
11.0	PHR (PHY)	M.E. Celep	**1**	1	1	**3**
8.5, U6.5	RAD	Ö. Sarıca	**1**	1	1	**3**
7.0, U6.2	EM	E. G. Gencer	**1**	0	0	**1**
1.0.-6.0	PED-S	Ş. Karaçay	**1**	0	0	**1**
1.0	HST	O. Akçın Alagöz	**1**	0	0	**1**
1.0.-6.0	GS	G. Tellioğlu	**1**	0	0	**1**
		TOTAL	**100**	**47**	**47**	**184**

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0, 4 - 8.10	END	H. Aydın		-	-	**1**
1.0-8.10	OBS-GYN	R. Attar		-	-	**1**
U1.0 - U6.0	NE	G. Kantarcı		-	-	**1**
U1.0.-U6.10	URO	M. Kuru		-	-	**1**
1.0, 4.0, 7.0, 8.4, U1, U2, U6.4	PT	F. Özkan		-	-	**1**
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** point; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam; **pts:** Points
****45** out of 200 FE and ICE MCQs will be from Committee IV (Each question is of worth **0.5** pts).

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEM
WEEK I / 22 – 26 Feb 2021

	Monday 22-Feb-2021	Tuesday 23-Feb-2021	Wednesday 24-Feb-2021	Thursday 25-Feb-2021				Friday 26-Feb-2021	
09.00- 09.50	**Lecture** Introduction to Endocrinology H. Aydın	**Lecture** Pathology of Adrenal Gland I A. Sav	**Lecture** Pathophysiology of Endocrine System Diseases I M. Kaçar	**ICP-CSL** (Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP Smear Obtaining) R. Attar / G. Yıldırım				**Lecture** Introduction to Endocrine Pharmacology E. Genç	
10.00- 10.50	**Lecture** Introduction to Diabetes Mellitus H. Aydın	**Lecture** Pathology of Adrenal Gland II A. Sav	**Lecture** Pathophysiology of Endocrine System Diseases II M. Kaçar	**Group A ICP**	**Group B** **Small Group Study** SRPC	**Group C IL**	**Group D IL**	**Lecture** Thyroid and Antithyroid Drugs I E. Genç	
11.00- 11.50	**Lecture** Clinical and Laboratory Findings of Diabetes Mellitus H. Aydın	**Lecture** Relation Between Two Variables I Ç. Altunok	**Lecture** Pathophysiology of Endocrine System Diseases III M. Kaçar					**Lecture** Thyroid and Antithyroid Drugs II E. Genç	
12.00- 12.50	**Lecture** Obesity H. Aydın	**Lecture** Relation Between Two Variables II Ç. Altunok	**Lecture** Hypertensive Disorders in Pregnancy E.G. Gencer	**Lecture** Normal Pubertal Development B. Haliloğlu				**Lecture** Pathology of Pancreas II A. Sav	
12.50 – 14.00	**LUNCH BREAK**								
14.00- 14.50	**Lecture** Pathology of Endocrine System: Introduction A. Sav	**Lecture** Calcium Metabolism H. Aydın	**Lecture** Prenatal Genetic Diagnosis A. Ç. Kuşkucu	**Lecture** Congenital Adrenal Hyperplasia B. Haliloğlu				**ELECTIVE COURSE WEEK II**	**Independent Learning**
15.00- 15.50	**Lecture** Pathology of Pituitary Gland I A. Sav	**Lecture** Physical Examination of Newborn Patient M. Berber	**Lecture** Genetic Counseling A. Ç. Kuşkucu	**Lecture** Pubertal Disorders B. Haliloğlu					
16.00- 16.50	**Lecture** Pathology of Pituitary Gland II A. Sav	**Lecture** Physical Examination of Child Patient M. Berber	**Lecture** Pathology of Thyroid & Parathyroid I A. Sav	**Lecture** Hypoglycemia H. Aydın				**Independent Learning**	**ELECTIVE COURSE WEEK II**
17.00-17.50	**Lecture** Pathology of Pancreas I A. Sav	**Lecture** Imaging of Thyroid Glands Ö. Sarıca	**Lecture** Pathology of Thyroid & Parathyroid II A. Sav	**Lecture** Hypercalcemic Diseases H. Aydın					

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK II / 1 – 5 Mar 2021

<table>
<tr><th></th><th>Monday
1-Mar-2021</th><th>Tuesday
2-Mar-2021</th><th>Wednesday
3-Mar-2021</th><th>Thursday
4-Mar-2021</th><th colspan="4">Friday
5-Mar-2021</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Puerperal Infections
T. Demirören</td><td>Lecture
Fluid, Electrolyte I
G. Kantarcı</td><td>Independent Learning</td><td>Lecture
Renovascular Pathology
E. Hacıhasanoğlu</td><td colspan="4">ICP-CSL
(Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP Smear Obtaining)
R. Attar / G. Yıldırım</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Normal and Abnormal Labor
T. Demirören</td><td>Lecture
Fluid, Electrolyte II
G. Kantarcı</td><td>Independent Learning</td><td>Lecture
Renal Cystic Disease
E. Hacıhasanoğlu</td><td rowspan="2">Group A
Small Group Study
SRPC</td><td rowspan="2">Group B
ICP</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Insulin and Oral Antidiabetic Drugs I
E. Genç</td><td>Lecture
Hyperfunctioning Disorders of Anterior Pituitary Gland
F. Keleştimur</td><td>Lecture
The Gynecological History and Examination
G. Yıldırım</td><td>Career Festival
Ş. Göktaş</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Insulin and Oral Antidiabetic Drugs II
E. Genç</td><td>Lecture
Disorders of Posterior Pituitary Gland
F. Keleştimur</td><td>Lecture
Endometriosis & Adenomyosis
G. Yıldırım</td><td>Career Festival
S. Tunç</td><td colspan="4">Independent Learning</td></tr>
<tr><td>12.50-14.00</td><td colspan="8">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Pathology of Vulva & Vagina
F. Özkan</td><td>Lecture
Hypopituatirism
F. Keleştimur</td><td>Lecture
Adrenocortical Hormones and Drugs I
E. Genç</td><td>Lecture
Reproductive Ethics
E. Vatanoğlu Lutz</td><td colspan="2" rowspan="2">ELECTIVE WEEK III</td><td colspan="2" rowspan="2">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Pathology of Treponemal Infections
F. Özkan</td><td>Lecture
Diffuse Hormonal Systems and Endocrine Tumor Syndromes
H. Aydın</td><td>Lecture
Adrenocortical Hormones and Drugs II
E. Genç</td><td>Lecture
Gene Ethics
E. Vatanoğlu Lutz</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Pathology of Breast I
F. Özkan</td><td>Lecture
Thyroid Function Tests
H. Aydın</td><td>Lecture
Antenatal Care
T. Demirören</td><td>Lecture
Medical History for Breast Diseases in Primary Care & Clinical Breast Examination
A. Akalın</td><td colspan="2" rowspan="2">Independent Learning</td><td colspan="2" rowspan="2">ELECTIVE WEEK III</td></tr>
<tr><td>17.00-17.50</td><td>Lecture
Pathology of Breast II
F. Özkan</td><td>Lecture
Thyroid Disorders
H. Aydın</td><td>Lecture
Disorders of Early Pregnancy (Miscarriage; Ectopic; GTD)
T. Demirören</td><td>Lecture
Imaging of Urinary System
Ö. Sarıca</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS
WEEK III / 8 – 12 Mar 2020

<table>
<tr><th></th><th>Monday
8-Mar-2021</th><th>Tuesday
9-Mar-2021</th><th>Wednesday
10-Mar-2021</th><th>Thursday
11-Mar-2021</th><th>Friday
12-Mar-2021</th></tr>
<tr><td>09.00-09.50</td><td>Lecture
Pathophysiology of Reproductive System Diseases I
M. Kaçar</td><td>Lecture
Menopause
E. Attar</td><td>Lecture
Immunology of Reproduction
G. Yanıkkaya Demirel</td><td colspan="4">ICP-CSL
(Physical Examination of the Newborn and Child Patient)
Ç. Ayanoğlu/
M. Berber</td><td>Lecture
Congenital Infections and Sexually Transmitted Diseases, Genital Infections I
M. Sönmezoğlu</td></tr>
<tr><td>10.00-10.50</td><td>Lecture
Pathophysiology of Reproductive System Diseases II
M. Kaçar</td><td>Lecture
Fertility Control
E. Attar</td><td>Lecture
Immunology of Reproduction
G. Yanıkkaya Demirel</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group C ICP</td><td rowspan="2">Group D
Small Group Study
SRPC</td><td>Lecture
Congenital Infections and Sexually Transmitted Diseases, Genital Infections II
M. Sönmezoğlu</td></tr>
<tr><td>11.00-11.50</td><td>Lecture
Phytotherapy-VII
M. E. Celep</td><td>Lecture
Infertility
E. Attar</td><td>Lecture
Hypocalcemic Diseases
H. Aydın</td><td>Lecture
Congenital Infections and Sexually Transmitted Diseases, Genital Infections III
M. Sönmezoğlu</td></tr>
<tr><td>12.00-12.50</td><td>Lecture
Phytotherapy-VIII
M. E. Celep</td><td>Lecture
The Menstrual Cycle and Disorders of the Menstrual Cycle
R. Attar</td><td>Lecture
Adrenal Disorders
H. Aydın</td><td colspan="4">Lecture
Normal and Abnormal Sexual Development & Puberty
R. Attar</td><td>Lecture
Congenital Anomalies of The Urinary System
Ş. Karaçay</td></tr>
<tr><td>12.50-14.00</td><td colspan="6">LUNCH BREAK</td></tr>
<tr><td>14.00-14.50</td><td colspan="2">Microbiology Laboratory
(Diagnostic Tests of Urinary Specimens)
İ. Ç. Acuner</td><td colspan="2">Microbiology Laboratory
(Diagnostic Tests of Urinary Specimens)
İ. Ç. Acuner</td><td>Lecture
Conditions Affecting Vulva & Vagina
O. Ünal</td><td colspan="4">ICP-CSL
(Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP)
R. Attar / G. Yıldırım</td><td rowspan="2">ELECTIVE WEEK IV</td><td rowspan="2">Independent Learning</td></tr>
<tr><td>15.00-15.50</td><td>Group A</td><td>Group B IL</td><td>Group C IL</td><td>Group D IL</td><td>Microbiology Laboratory
(Diagnostic tests of urinary specimens)
İ. Ç. Acuner</td><td>Group C</td><td>Group D IL</td><td>Group A & B IL</td><td>Lecture
Pathology of Bladder
E. Hacıhasanoğlu</td><td>Group A IL</td><td>Group B IL</td><td>Group C
Small Group Study
SRPC</td><td>Group D ICP</td></tr>
<tr><td>16.00-16.50</td><td>Group A IL</td><td>Group B</td><td>Group C IL</td><td>Group D</td><td colspan="2">Independent Learning</td><td colspan="2">Independent Learning</td><td>Independent Learning</td><td>ELECTIVE WEEK IV</td></tr>
<tr><td>17.00-17.50</td><td colspan="2">Independent Learning</td><td colspan="2">Independent learning</td><td>Independent Learning</td><td colspan="4">Independent Learning</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK IV / 15 – 19 Mar 2021

	Monday 15-Mar-2021	Tuesday 16-Mar-2021	Wednesday 17-Mar-2021	Thursday 18-Mar-2021	Friday 19-Mar-2021	
09.00- 09.50	**Lecture** Pathology of Glomerular Diseases I E. Hacıhasanoğlu	**Lecture** Pathology of Ovary I F. Özkan	**Lecture** Benign Diseases of the Uterus and the Cervix R. Attar	**Lecture** Pathology of Urinary System Tumors E. Hacıhasanoğlu	**Lecture** Pathology of Cervix Uteri I F. Özkan	
10.00- 10.50	**Lecture** Pathology of Glomerular Diseases II E. Hacıhasanoğlu	**Lecture** Pathology of Ovary II F. Özkan	**Lecture** Benign Diseases of the Ovary R. Attar	**Lecture** Congenital Anomalies of Urinary System E. Hacıhasanoğlu	**Lecture** Pathology of Cervix Uteri II F. Özkan	
11.00- 11.50	**Lecture** Pathology of Glomerular Diseases III E. Hacıhasanoğlu	**Lecture** Pathology of Tubulointerstitial Disease I E. Hacıhasanoğlu	**Lecture** Nephritic Syndrome G. Kantarcı	**Lecture** Genetic disorders of gonadal development A. Ç. Kuşkucu	**Lecture** Chromosomal Disorders I A. Ç. Kuşkucu	
12.00- 12.50	**Lecture** Androgens & Anabolic Steroids E. Genç	**Lecture** Pathology of Tubulointerstitial Disease II E. Hacıhasanoğlu	**Lecture** Nephrotic Syndrome G. Kantarcı	**Lecture** Genetic disorders of gonadal development A. Ç. Kuşkucu	**Lecture** Chromosomal Disorders II (Sex Chromosomes and their Abnormalities) A. Ç. Kuşkucu	
12.50 – 14.00	**LUNCH BREAK**					
14.00- 14.50	**Lecture** Malign Diseases of the Uterus and the Cervix O. Ünal	**Lecture** Acute Kidney Injury-I G. Kantarcı	**Independent Learning**	**Lecture** Pathology of Uterus I F. Özkan	**ELECTIVE WEEK V**	**Independent Learning**
15.00- 15.50	**Lecture** Malign Diseases of the Ovary O. Ünal	**Lecture** Acute Kidney Injury-II G. Kantarcı	**ICP-CSL** (Clinical Breast Examination) A. Akalın/ Ö. Tanrıöver	**Lecture** Pathology of Uterus II F. Özkan		
16.00- 16.50	**Lecture** Conditions Affecting Vulva & Vagina O. Ünal	**Lecture** Agents Effecting Bone Mineral Homeostasis I E. Genç	**Group A IL** / **Group B IL** / **Group C Small Group Study** SRPC / **Group D**	**Lecture** The Kidney Systemic Disease and Inherited Disorders G. Kantarcı	**Independent Learning**	**ELECTIVE WEEK V**
17.00-17.50	**Lecture** Pathology of Pregnancy & Placenta F. Özkan	**Lecture** Agents Effecting Bone Mineral Homeostasis II E. Genç		**Lecture** The Kidney Systemic Disease and Inherited Disorders G. Kantarcı		

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK V / 22 – 26 Mar 2021

<table>
<tr><th></th><th>Monday
22-Mar-2020</th><th>Tuesday
23-Mar-2020</th><th>Wednesday
24-Mar-2020</th><th>Thursday
25-Mar-2020</th><th colspan="4">Friday
26-Mar-2020</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Benign Prostatic Hyperplasia-I
M. Kuru</td><td>Lecture
Chronic Kidney Disease
G. Kantarcı</td><td>Lecture
Epidemiology, Prevention and Control of Type II Diabetes Mellitus
R. E. Sezer</td><td>Independent Learning</td><td rowspan="2">Microbiology Laboratory
(Diagnostic Tests of Urogenital Specimens)
Microbiology Instructors</td><td>Group D</td><td>Group C IL</td><td rowspan="2">Group A & B IL</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Benign Prostatic Hyperplasia-II
M. Kuru</td><td>Lecture
Chronic Kidney Disease
G. Kantarcı</td><td>Lecture
Acid/ Base Balance I
G. Kantarcı</td><td>Lecture
Reproductive, Maternal and Child Health II
H. A. Taşyıkan</td><td>Group D IL</td><td>Group C</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Urologic Emergencies
M. Kuru</td><td>Lecture
Estrogens, Progestines and Inhibitors I
E. N. Özdamar</td><td>Lecture
Acid/ Base Balance II
G. Kantarcı</td><td>Lecture
Reproductive, Maternal and Child Health II
H. A. Taşyıkan</td><td rowspan="2">Microbiology Laboratory
(Diagnostic Tests of Urogenital Specimens)
Microbiology Instructors</td><td rowspan="2">Group D & C IL</td><td>Group B</td><td>Group A IL</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Approach to the Patient with Urinary Tract Symptoms
M. Kuru</td><td>Lecture
Estrogens, Progestines and Inhibitors II
E. N. Özdamar</td><td>Lecture
Clinical Study of Renal Functions and Urinary Findings
G. Kantarcı</td><td>Lecture
Reproductive, Maternal and Child Health II
H. A. Taşyıkan</td><td>Group B IL</td><td>Group A</td></tr>
<tr><td>12.50 -14.00</td><td colspan="8">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td colspan="3">ICP-CSL
(Clinical Breast Examination)
A. Akalın/ Ö. Tanrıöver</td><td colspan="2">ICP-CSL
(Clinical Breast Examination)
A. Akalın/ Ö. Tanrıöver</td><td>Independent Learning</td><td>Lecture
Urologic Oncology I
M. Kuru</td><td colspan="2" rowspan="2">ELECTIVE WEEK VI</td><td colspan="2" rowspan="2">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="2">Group A
Small Group Study
SRPC</td><td rowspan="2">Group B ICP</td><td rowspan="2">Group C & D IL</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group C ICP</td><td rowspan="2">Group D
Small Group Study
SRPC</td><td colspan="4">ICP-CSL
(Clinical Breast Examination)
A. Akalın/ Ö. Tanrıöver</td><td>Lecture
Urologic Oncology II
M. Kuru</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="2">Group B
Small Group Study
SRPC</td><td rowspan="2">Group A ICP</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td><td>Lecture
Upper and Lower Urinary Tract Infections I
Lecturer</td><td rowspan="2">Independent Learning</td><td colspan="2" rowspan="2">ELECTIVE WEEK VI</td></tr>
<tr><td>17.00-17.50</td><td colspan="3">Independent Learning</td><td colspan="3">Independent Learning</td><td>Lecture
Upper and Lower Urinary Tract Infections II
Lecturer</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK VI / 29 Mar – 2 Apr 2021

<table>
<tr><th></th><th colspan="3">Monday
29-Mar-2020</th><th>Tuesday
30-Mar-2020</th><th>Wednesday
31-Mar-2020</th><th colspan="4">Thursday
1-Apr-2020</th><th colspan="2">Friday
2-Apr-2020</th></tr>
<tr><td>09.00- 09.50</td><td colspan="3">Lecture
Pathophysiology of Urinary System Diseases I
M. Kaçar</td><td>Lecture
Hypothalamic and Pituitary Hormones I
E. N. Özdamar</td><td>Multidisciplinary Case Discussion Panel</td><td colspan="4">Independent Learning</td><td colspan="2">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="3">Lecture
Pathophysiology of Urinary System Diseases II
M. Kaçar</td><td>Lecture
Hypothalamic and Pituitary Hormones II
E. N. Özdamar</td><td>Multidisciplinary Case Discussion Panel</td><td colspan="4">ICP-CSL
(Physical Examination of the Newborn and Child Patient)
Ç. Ayanoğlu/
M. Berber</td><td colspan="2">Independent Learning</td></tr>
<tr><td>11.00- 11.50</td><td colspan="3">Lecture
Pathology of Male Genital System I
E. Hacıhasanoğlu</td><td>Lecture
Relation Between Several Variables
Ç. Altunok</td><td>Lecture
Tubulointerstitial Diseases
G. Kantarcı</td><td rowspan="2">Group A ICP-CSL</td><td rowspan="2">Group B ICP-CSL</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td><td colspan="2">Independent Learning</td></tr>
<tr><td>12.00- 12.50</td><td colspan="3">Lecture
Pathology of Male Genital System II
E. Hacıhasanoğlu</td><td>Lecture
Transplantation of Kidney
G. Tellioğlu</td><td>Lecture
Tubulointerstitial Diseases
G. Kantarcı</td><td colspan="2">Independent Learning</td></tr>
<tr><td>12.50- 14.00</td><td colspan="9">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="2">Pathology Laboratory
(Urinary System)
A.Sav / F. Özkan</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B</td><td>Lecture
Nephritic and Nephrotic Syndrome
T. Coşkun</td><td>Lecture
Delivery of Family Planning Services I
A. Akalın</td><td colspan="4">ICP-CSL
(Physical Examination of the Newborn and Child Patient)
Ç. Ayanoğlu/
M. Berber</td><td rowspan="2">ELECTIVE COURSE WEEK VII MID-TERM EXAM</td><td rowspan="2">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
General Approach to the Pregnant Woman
Ö. Tanrıöver</td><td>Lecture
Delivery of Family Planning Services II
A. Akalın</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group C ICP-CSL</td><td rowspan="2">Group D ICP-CSL</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="2">Pathology Laboratory
(Urinary System)
A.Sav / F. Özkan</td><td rowspan="2">Group A</td><td rowspan="2">Group B IL</td><td>Lecture
Embryology
O. Alagöz</td><td>Independent Learning</td><td rowspan="2">Independent Learning</td><td rowspan="2">ELECTIVE COURSE WEEK VII MID-TERM EXAM</td></tr>
<tr><td>17.00-17.50</td><td>Independent Learning</td><td>Independent Learning</td><td colspan="4">Independent Learning</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK VII / 5 – 9 Apr 2021

<table>
<tr><th></th><th>Monday
5-Apr-2021</th><th>Tuesday
6-Apr-2021</th><th>Wednesday
7-Apr-2021</th><th>Thursday
8-Apr-2021</th><th colspan="2">Friday
9-Apr-2021</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td colspan="2">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="2" rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td colspan="4">LUNCH BREAK</td><td colspan="2">Program Evaluation Session
Committee IV
Coordination Committee Members</td></tr>
<tr><td>12.50- 14.00</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="2">ELECTIVE
WEEK VIII</td><td rowspan="2">Independent
Learning</td></tr>
<tr><td>14.00- 14.50</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="2">Independent
Learning</td><td rowspan="2">ELECTIVE
WEEK VIII</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td><td colspan="2"></td></tr>
</table>

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY

DISTRIBUTION of LECTURE HOURS

April 12, 2021 – May 28, 2021

COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	NEUROSURGERY	NRS	15	1x2=2 (2 Groups)			**17**
	NEUROLOGY	NR	13	1x4=4 (2 Groups)			**17**
	PHARMACOLOGY	PC	17				**17**
	PATHOLOGY	PT	11		1x2=2 (2 Groups)		**13**
	PSYCHIATRY	PCH	12				**12**
	PEDIATRICS	PED	4				**4**
	PUBLIC HEALTH	PH	4				**4**
	FAMILY MEDICINE	FM	3				**3**
	BIOISTATISTICS	BS	3				**3**
	CHILD PSYCHIATRY	C-PCH	3				**3**
	MEDICAL GENETICS	MG	3				**3**
	OPHTALMOLOGY	OPT	3				**3**
	PATHOPHYSIOLOGY	PP	2				**2**
	IMMUNOLOGY	IMM	2				**2**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	2				**2**
	RADIOLOGY	RAD	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		99	6	2	2	**109**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				1x2=2 (4 Groups)	**2**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			2x3=6 (4 Groups)		**6**
TOTAL			**100**	**6**	**8**	**4**	**117**
	INDEPENDENT LEARNING						**103**

Coordination Committee

HEAD	N. Berfu Akbaş, MD, Assoc. Prof.
SECRETARY	Hakan Şilek, MD, Assist. Prof.
MEMBER	Vildan Öztürk, MD, Assist. Prof.
MEMBER	Okan Taycan, MD, Assoc. Prof.
MEMBER	Erdem Söztutar, MD, Assist. Prof.

COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY
LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
NEUROLOGY	Berrin Aktekin, MD, Prof. Halide Rengin Bilgen, MD Hakan Şilek, MD
PSYCHIATRY	Hakan Atalay, MD, Assoc. Prof. Okan Taycan, MD, Assoc. Prof.
CHILD PSYCHIATRY	Oğuzhan Zahmacıoğlu, MD, Assist. Prof
NEUROSURGERY	M.Gazi Yaşargil, MD, Prof. Uğur Türe, MD, Prof. Ahmet Hilmi Kaya, MD, Prof.
PATHOLOGY	Aydın Sav, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof.
PEDIATRICS	Mustafa Berber, MD, Assist. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc. Prof. Özlem Tanrıöver, MD, Prof.
RADIOLOGY	O.Melih Topçuoğlu, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof.
OPHTALMOLOGY	Vildan Öztürk, MD, Assist. Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
EMERGENCY MEDICINE	Cem Şimşek, MD, Assist. Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Halide Rengin Bilgen, MD, Assist. Prof. Hakan Şilek, MD, Assoc. Prof. Naz Berfu Akbaş, MD, Assoc. Prof. Oğuzhan Zahmacıoğlu, MD Assoc. Prof. Dilek Barutçu Ataş, MD, Assist. Prof. Kübra Yıldız, MD, Assist. Prof.

AIMS and LEARNING OBJECTIVES

AIMS

In evidence-based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of nervous system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
5. ***to convey*** knowledge on mechanism of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision-making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on drugs that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,
8. ***to convey*** necessary knowledge on professional standards, organizational ethics, and ethics of psychiatry***,***
9. ***to convey*** necessary knowledge on common problems in medical research,
10. ***to convey*** knowledge on phytotherapeutic agents,
11. ***to equip with*** basic and advanced clinical skills *(suturing and tying-C7, neuropsychiatric evaluation-C7)* required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0 ***recall*** anatomy, histology and physiology of nervous system,

2.0 ***define*** biochemical and psychodynamical basis of behavior,

3.0 ***grade*** physical, psychosocial and cognitive development of child,

4.0 ***explain*** etiopathogenesis of clinical conditions (central and peripheral nervous system disorders, epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,

5.0 ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to to nervous system and psychiatry,

6.0 ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,

7.0 ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,

8.0 at multi-system level and/or related to cardiovascular and respiratory systems system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision-making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

8.1. practice of history taking and physical examination (neurological/neuropsychiatric-C7)

8.2. evaluation of emergency case (neurological emergencies-C7)

8.3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depression-C7, dementia-C7)

8.4. laboratory tests/examinations

8.5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, brain perfusion scintigraphy-C7, brain PET-C7)

8.6. point of care testing

8.7. making preliminary diagnosis or definitive diagnosis decision

8.8. making non-intervention or intervention decision

8.9. practicing non-intervention or intervention

8.10. referral/transport of healthy individual or patient

9.0 ***explain*** pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS stimulants and hallusinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists, general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs, alcohols, drug dependence and abuse) that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,

10.0 ***describe*** professional standards, organizational ethics, and ethics in psychiatry,

11.0 ***list*** common problems in medical research,

12.0 ***perform*** basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7), required at primary health care service.

COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MED 302 INTRODUCTION to CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**DISCIPLINE**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
9.0	PC	E. Genç E. N. Özdamar	14	5	5	**24**
1.0, 4.0-8.0	NRS	M.G. Yaşargil U. Türe A.H. Kaya V. Harput	14	5	5	**24**
1.0, 4.0-8.0	NR	B. Aktekin H. Şilek H. R. Bilgen	12	4	4	**20**
1.0, 2.0, 4.0-8.0, 10.0	PCH	H. Atalay	10	4	4	**18**
1.0, 4.0, 7.0	PT	A. Sav	9	3	3	**15**
1.0, 3.0-8.0	PED	M. Berber	4	1	1	**6**
4.0, 7.0	IMM	G. Y. Demirel	2	1	1	**4**
5.0, 6.0	PH	R.E. Sezer	3	1	1	**5**
8.3	FM	G. İzbırak Ö. Tanrıöver	4	1	1	**6**
11.0	BS	Ç. Altunok	3	1	1	**5**
2.0	MG	A.Ç. Kuşkucu	3	1	1	**5**
2.0-8.0, 10.0	C-PCH	O. Zahmacıoğlu	3	1	1	**5**
1.0, 4.0-8.0	OPT	V. Öztürk	3	1	1	**5**
4.0, 7.0	PP	M. Kaçar	2	1	1	**4**
4.0-7.0, 8.4	IDCM	M. Sönmezoğlu	2	1	1	**4**
8.5	RAD	O.M. Topçuoğlu	1	0	0	**1**
8.2	EM	C. Şimşek	1	0	0	**1**
TOTAL			**90**	**31**	**31**	**152**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/INSTRUCTOR**	**NUMBER of QUESTIONS (EMQ)**			
			CE	**FE**	**IE**	**Total**
1.0., 4.0.-8.0.	NR	B. Örmeci	2	-	-	**2**
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	B. Akbaş	2	-	-	**2**
1.0., 4.0.-8.0.	NRS	U. Türe	1	-	-	**1**
TOTAL			**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****31** out of 200 FE and ICE MCQs will be from Committee V (Each question is of worth 0.5 points).

COMMITTEE V - NERVOUS SYSTEM and PYSCHIATRY
WEEK I / 12 – 16 Apr 2021

	Monday 12-Apr-2021	Tuesday 13-Apr-2021	Wednesday 14-Apr-2021	Thursday 15-Apr-2021	Friday 16-Apr-2021	
09.00- 09.50	**Independent Learning**	**Lecture** Pathology of Myelin & Neuronal Storage Diseases I A. Sav	**Lecture** Epilepsy B. Aktekin	**Independent Learning**	**Lecture** Pharmacological Approach to Parkinsonism & Other Movement Disorders I E. Genç	
10.00- 10.50	**Lecture** Signs and Symptoms in Neurology B. Aktekin	**Lecture** Pathology of Myelin & Neuronal Storage Diseases II A. Sav	**Lecture** Peripheral Nerve Compression Sydromes A. H. Kaya	**Lecture** Surgical Neuroanatomy U. Türe	**Lecture** Pharmacological Approach to Parkinsonism & Other Movement Disorders II E. Genç	
11.00- 11.50	**Lecture** Cranial Nerves I R. Bilgen	**Lecture** Developmental Disorders of CNS A. Sav	**Lecture** Spinal Cord Compression and Spinal Tumors A. H. Kaya	**Lecture** Cerebrovascular Diseases in Neurosurgery I U. Türe	**Lecture** Headache in Neurologic Patient H. Şilek	
12.00- 12.50	**Lecture** Cranial Nerves II R. Bilgen	**Lecture** Introduction to Central Nervous System Pharmacology E. Genç	**Lecture** Degenerative Diseases of the Spine and the Spinal Cord A. H. Kaya	**Lecture** Cerebrovascular Diseases in Neurosurgery II U. Türe	**Lecture** Neurological Emergencies R. Bilgen	
12.50 – 14.00	**LUNCH BREAK**					
14.00- 14.50	**Lecture** Pathophysiology of Nervous System Diseases I M. Kaçar	**Lecture** Demyelinating Disorders I R. Bilgen	**Lecture** Cerebral Lobes and their Disorders B. Aktekin	**Independent Learning**	**ELECTIVE WEEK IX**	**Independent Learning**
15.00- 15.50	**Lecture** Pathophysiology of Nervous System Diseases II M. Kaçar	**Lecture** Demyelinating Disorders II R. Bilgen	**Lecture** Dementia R. Bilgen	**Independent Learning**		
16.00- 16.50	**Lecture** Neuroimmunological Disorders G. Yanıkkaya Demirel	**Lecture** Approach to Intoxicated Patient C. Şimşek	**Lecture** Extrapyramidal System Disorders H. Şilek	**Independent Learning**	**Independent Learning**	**ELECTIVE WEEK IX**
17.00-17.50	**Lecture** Neuroimmunological Disorders G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**	**Independent Learning**		

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE V - NERVOUS SYSTEM and PYSCHIATRY
WEEK II / 19 – 23 Apr 2021

	Monday 19-Apr-2021	Tuesday 20-Apr-2021	Wednesday 21-Apr-2021	Thursday 22-Apr-2021	Friday 23-Apr-2021
09.00- 09.50	**Lecture** Clinical Presentation, Anatomic Concepts and Diagnosis in a Neurosurgical Patient Lecturer	**Lecture** Public Health and Aging I R. E. Sezer	**Neurology Clinical Training** H.Şilek	**Neurology Clinical Training** H. Şilek	**NATIONAL HOLIDAY**
10.00- 10.50	**Lecture** Pediatric Neurosurgery Lecturer	**Lecture** Public Health and Aging II R. E. Sezer	**Group A** / **Group B** / **Group C IL** / **Group D IL**	**Group A IL** / **Group B IL** / **Group C** / **Group D**	
11.00- 11.50	**Lecture** Hydrocephalus Lecturer	**Lecture** Paralytic Strabismus and Nistagmus V. Öztürk			
12.00- 12.50	**Lecture** Neurosurgical Infections Lecturer	**Lecture** Conventional Neuroradiological Examinations O. M. Topçuoğlu			
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Neurodegenerative Disorders I A. Sav	**Lecture** Infectious Disease of the Nervous System M. Berber	**Lecture** Peripheral Nerve Disorders H. Şilek	**Lecture** Cranial Trauma & Intracranial Hemorrhage I A. Sav	**NATIONAL HOLIDAY**
15.00- 15.50	**Lecture** Neurodegenerative Disorders II A. Sav	**Lecture** Neurodegenerative Disorders M. Berber	**Lecture** Cerebrovascular Disease H. Şilek	**Lecture** Cranial Trauma & Intracranial Hemorrhage II A. Sav	
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	

COMMITTEE V - NERVOUS SYSTEM and PYSCHIATRY
WEEK III / 26 – 30 Apr 2021

	Monday 26-Apr-2021	Tuesday 27-Apr-2021	Wednesday 28-Apr-2021	Thursday 29-Apr-2021	Friday 30-Apr-2021
09.00- 09.50	**Lecture** Tumors of CNS I A. Sav	**Lecture** Antiepileptics E. Genç	**Neurosurgery Clinical Training** Lecturer	**Pathology Laboratory Lecture** Nervous System A.Sav	**Neurosurgery Clinical Training** Lecturer
10.00- 10.50	**Lecture** Tumors of CNS II A. Sav	**Lecture** Functional Neurosurgery Lecturer	**Group A** / **Group B** / **Group C IL** / **Group D IL**	**Pathology Laboratory Lecture** Nervous System A.Sav	**Group A IL** / **Group B IL** / **Group C** / **Group D**
11.00- 11.50	**Lecture** Intracranial Tumors II M. Gazi Yaşargil	**Lecture** Spinal Trauma in Neurosurgery Lecturer	**Lecture** Genetic Etiology of Mental Retardation I A. Ç. Kuşkucu	**Pathology Laboratory Lecture** Nervous System A.Sav	**Lecture** Cerebral Malformations M. Berber
12.00- 12.50	**Lecture** Intracranial Tumors I M. Gazi Yaşargil	**Lecture** Cranial Trauma in Neurosurgery Lecturer	**Lecture** Genetic Etiology of Mental Retardation II A. Ç. Kuşkucu	**Pathology Laboratory Lecture** Nervous System A.Sav	**Lecture** Mental and Motor Development M. Berber
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Bipolar Disease & Lithium E. N. Özdamar	**Lecture** Culture, Health and Illness R. E. Sezer	**Lecture** Diseases of Optic Nerves and Visual Fields V. Öztürk	**ICP-CSL** (Neurological Examination & Psychiatric Examination) N.B. Akbaş / O. Zahmacıoğlu/ H. Şilek	**ELECTIVE WEEK X** / **Independent Learning**
15.00- 15.50	**Lecture** Antipsychotic Drugs E. N. Özdamar	**Lecture** Behavioral Determinants of Health and Disease R. E. Sezer	**Lecture** Pupilla V. Öztürk	**Group A IL** / **Group B IL** / **Group D** Small Group Study SRPC / **Group C ICP**	
16.00- 16.50	**Lecture** Approach to Smoking Patient in Primary Care Ö. Tanrıöver	**Independent Learning**	**Independent Learning**		**Independent Learning** / **ELECTIVE WEEK X**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**		

COMMITTEE V - NERVOUS SYSTEM and PYSCHIATRY
WEEK IV / 3 – 7 May 2021

	Monday 3-May-2021	Tuesday 4-May-2021	Wednesday 5-May-2021	Thursday 6-May-2021	Friday 7-May-2021	
09.00- 09.50	**Lecture** Opioid Analgesics & Antagonists I E. Genç	**Lecture** Introduction to Psychiatry O. Taycan	**ICP-CSL** (General Physical Examination) D. B. Ataş/ K. Yıldız	**ICP-CSL** (Neurological Examination & Psychiatric Examination) N. B. Akbaş/ O. Zahmacıoğlu/ H. Şilek	**Lecture** Analysis of Survival Studies I Ç. Altunok	
10.00- 10.50	**Lecture** Opioid Analgesics & Antagonists II E. Genç	**Lecture** Psychiatric Interview, History O. Taycan	**Group A ICP** / **Group B IL** / **Group C IL** / **Group D IL**	**Group A** Small Group Study SRPC / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Analysis of Survival Studies II Ç. Altunok	
11.00- 11.50	**Lecture** Psychiatric Epidemiology and Classification N.B. Akbaş	**Lecture** Acute and Chronic Meningitis, Encephalitis I M. Sönmezoğlu			**Lecture** Local Anesthetics E. Genç	
12.00- 12.50	**Lecture** Antimigraine Drugs E. N. Özdamar	**Lecture** Acute and Chronic Meningitis, Encephalitis II M. Sönmezoğlu	**Independent Learning**	**Independent Learning**	**Lecture** General Anesthetics E. Genç	
12.50 – 14.00	**LUNCH BREAK**					
14.00- 14.50	**Lecture** Infectious Diseases of CNS I A. Sav	**Lecture** Design of Survival Studies Ç. Altunok	**ICP-CSL** (Neurological Examination & Psychiatric Examination) N. B. Akbaş/ O. Zahmacıoğlu/ H. Şilek	**ICP-CSL** (General Physical Examination) D. B. Ataş / K. Yıldız	**ELECTIVE WEEK XI**	**Independent Learning**
15.00- 15.50	**Lecture** Infectious Diseases of CNS II A. Sav	**Lecture** General Physical Examination D. B. Ataş	**Group A ICP** / **Group B** Small Group Study SRPC / **Group C IL** / **Group D IL**	**Group A IL** / **Group B ICP** / **Group C IL** / **Group D IL**		
16.00- 16.50	**Independent Learning**	**Independent Learning**			**Independent Learning**	**ELECTIVE WEEK XI**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**		

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK V / 10 – 14 Apr 2021

	Monday 10-May-2021	Tuesday 11-May-2021	Wednesday 12-May-2021	Thursday 13-May-2021	Friday 14-May-2021
09.00- 09.50	**Lecture** Schizophrenia Spectrum and Other Psychotic Disorders I O. Taycan	**Lecture** Neuroscience I N.B. Akbaş	**Independent Learning**	**RAMADAN FEAST**	**RAMADAN FEAST**
10.00- 10.50	**Lecture** Schizophrenia Spectrum and Other Psychotic Disorders II O. Taycan	**Lecture** Neuroscience II N.B. Akbaş			
11.00- 11.50	**Lecture** Drug Dependence & Abuse E. Genç	**Lecture** Developmental Psychopathology: Risk and Protective Factors in Mental Development O. Taycan			
12.00- 12.50	**Lecture** The Alcohols E. Genç	**Lecture** Signs and Symptoms in Psychiatry O. Taycan			
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Genetic Aspects of Psychiatric Disorders A. Ç. Kuşkucu	**Independent Learning**	**RAMADAN FEAST EVE**	**RAMADAN FEAST**	**RAMADAN FEAST**
15.00- 15.50	**Lecture** Antidepressant Drugs E. N. Özdamar	**Independent Learning**			
16.00- 16.50	**Independent Learning**	**Independent Learning**			
17.00-17.50	**Independent Learning**	**Independent Learning**			

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK VI / 17 -21 May 2021

<table>
<tr><th></th><th>Monday
17-May-2021</th><th>Tuesday
18-May-2021</th><th>Wednesday
19-May-2021</th><th>Thursday
20-May-2021</th><th>Friday
21-May-2021</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Depression in Primary Care
G. İzbırak</td><td>Lecture
Introduction to Child and Adolescent Psychiatry
O. Zahmacıoğlu</td><td rowspan="4">COMMEMORATION OF ATATÜRK, YOUTH and SPORTS DAY</td><td colspan="4">ICP-CSL
(Neurological Examination & Psychiatric Examination)
N.B. Akbaş / O. Zahmacıoğlu/ H. Şilek</td><td colspan="4">ICP-CSL
(General Physical Examination)
D. B. Ataş / K. Yıldız</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Approach to the Patient with Dementia in Primary Care
G. İzbırak</td><td>Lecture
Common Childhood Psychiatric Problems
O. Zahmacıoğlu</td><td rowspan="3">Group A IL</td><td rowspan="3">Group B IL</td><td rowspan="3">Group D ICP</td><td rowspan="3">Group C Small Group Study SRPC</td><td>Group A IL</td><td>Group B IL</td><td>Group C ICP</td><td>Group D IL</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Sedative / Hypnotic Drugs I
E. Genç</td><td>Lecture
Mental Development in Childhood and Adolescence
O. Zahmacıoğlu</td><td colspan="4" rowspan="2">Independent Learning</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Sedative / Hypnotic Drugs II
E. Genç</td><td>Lecture
CNS Stimulants and Hallusinogenic Drugs
E. Genç</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Mood Disorders I
B. Akbaş</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="4">COMMEMORATION OF ATATÜRK, YOUTH and SPORTS DAY</td><td colspan="4">ICP-CSL
(General Physical Examination)
D. B. Ataş / K. Yıldız</td><td rowspan="2">ELECTIVE WEEK XII</td><td rowspan="2">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Mood Disorders II
B. Akbaş</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group D ICP</td><td rowspan="2">Group C IL</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Anxiety Disorders: An Introduction
B. Akbaş</td><td>Independent Learning</td><td rowspan="2">Independent Learning</td><td rowspan="2">ELECTIVE WEEK XII</td></tr>
<tr><td>17.00-17.50</td><td>Independent Learning</td><td>Independent Learning</td><td colspan="4">Independent Learning</td></tr>
</table>

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK VII / 24 – 28 May 2021

<table>
<tr><th></th><th>Monday
24-May-2021</th><th>Tuesday
25-May-2021</th><th>Wednesday
26-May-2021</th><th>Thursday
27-May-2021</th><th colspan="2">Friday
28-May-2021</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td colspan="2">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="2" rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td colspan="4">LUNCH BREAK</td><td colspan="2">Program Evaluation Session
Committee V
Coordination Committee
Members</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="2">ELECTIVE
WEEK XIII</td><td rowspan="2">Independent
Learning</td></tr>
<tr><td>15.00- 15.50</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="2">Independent
Learning</td><td rowspan="2">ELECTIVE
WEEK XIII</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

DISTRIBUTION of LECTURE HOURS

May 31, 2021 – July 02, 2021

COMMITTEE DURATION: 5 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	ORTHOPAEDICS & TRAUMATOLOGY	ORT	19				**19**
	PATHOLOGY	PT	13		1x2=2 (4 Groups)		**15**
	RHEUMATOLOGY	RHE	9				**9**
	PHARMACOLOGY	PC	5				**5**
	PHYSICAL MEDICINE AND REHABILITATION	PTR	4				**4**
	PUBLIC HEALTH	PH	4				**4**
	BIOSTATISTICS	BS	3				**3**
	PATHOPHYSIOLOGY	PP	2				**2**
	IMMUNOLOGY	IMM	2				**2**
	MEDICAL GENETICS	MG	2				**2**
	EMERGENCY MEDICINE	EM	2				**2**
	RADIOLOGY	RAD	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		66		2	2	**70**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				1x2=2 (4 Groups)	**2**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			1x3=3 (4 Groups)		**3**
TOTAL			**66**		**5**	**4**	**75**
	INDEPENDENT LEARNING						**81**

Coordination Committee

HEAD	Müge Bıçakçıgil Kalaycı, MD, Assoc. Prof
SECRETARY	Onur Kocadal, MD, Assist. Prof.
MEMBER	Gökhan Meriç, MD, Assoc. Prof.
MEMBER	Özgür Ortancıl, MD, Prof.
MEMBER	Pınar Tura, MD, Assist. Prof.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**FACULTY**
ORTHOPAEDICS & TRAUMATOLOGY	Faik Altıntaş, MD, Prof. Turhan Özler, MD, Assoc. Prof. Gökhan Meriç, MD, Assoc. Prof. Hakan Turan Çift, MD, Assoc. Prof. Onur Kocadal, MD, Assist. Prof. Burak Çağrı Aksu, MD, Assist. Prof.
PHYSICAL MEDICINE AND REHABILITATION	Özgür Ortancıl, MD, Prof.
RHEUMATOLOGY	Müge Bıçakçıgil Kalaycı, MD, Assoc. Prof
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Assoc. Prof Pınar Tura, MD, Assist. Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Hakan Turan Çift, MD, Assoc. Prof. Gökhan Meriç, MD, Assoc. Prof. Onur Kocadal, MD, Assist. Prof. Fırat Demircan, MD Utku Göktuğ, MD Süleyman Orman, MD Sermet Karagül, MD Murat Kuru, MD Mirkhakig Javadov, MD Burak Çağrı Aksu, MD Utku Göktuğ, MD

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of musculoskeletal system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to musculoskeletal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8. ***to convey*** necessary knowledge on ethics in biomedical research,
9. ***to convey*** necessary knowledge on clinical research methods and searching medical literature,
10. ***to convey*** necessary knowledge on phytotherapeutic agents,
11. ***to equip with*** basic and advanced clinical skills (peripheral venous catheter insertion-C8, physical examination of musculoskeletal system-C8) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0 ***recall*** anatomy, histology and physiology of musculoskeletal system,

2.0 ***explain*** etiopathogenesis of clinical conditions (congenital, traumatic, metabolic, degenerative, onocological conditions of bone, rheumotological disorders, disaeses/disorders of connective tissue, vascular diseases, pathological posture, pain) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

3.0 ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

4.0 ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,

5.0 ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

6.0 at multi-system level and/or related to cardiovascular and respiratory systems system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (musculoskeletal-C8)
6.2. evaluation of emergency case (trauma-C8)
6.3. approach to healthy individual or patient (musculoskeletal dysfunction-C8)
6.4. laboratory tests/examinations (monitarization of drug therapy-C8)
6.5. imaging tests/examinations (radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8, bone scintigraphy-C8)
6.6. point of care testing
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient

7.0 ***explain*** pharmacology of drugs (non-opioid analgesics, skeletal muscle relaxants, disease modifying antirheumatic drugs) that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,

8.0 ***explain*** effects of phytotherapeutic agents on musculoskeletal system or on clinical conditions related to musculoskeletal system,

9.0 ***explain*** use of biostatistics in clinical research and for evidence search in medical literature,

10.0 ***perform*** basic clinical skills, practiced on phantom models (peripheral venous catheter insertion-C8), and advanced clinical skills, practiced on simulated/standardized patients (physical examination of musculoskeletal system-C8), required at primary health care service.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MED 302 INTRODUCTION to CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE VI - MUSCULOSKELETAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**DISCIPLINE**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0-6.10	ORT	F. Altıntaş B. Ç. Aksu T. Özler G. Meriç O. Kocadal H. T. Çift	24	7	7	**38**
1.0, 2.0, 5.0	PT	F. Özkan A. Sav	18	4	4	**26**
1.0.-6.0	RHE	M. Bıçakçıgil Kalaycı	13	3	3	**19**
7.0.	PC	E. Genç E. N. Özdamar	7	2	2	**11**
3.0, 4.0	PH	R.E. Sezer H.A.Taşyıkan	5	1	1	**7**
1.0-6.0	PTR	Ö. Ortancıl	5	1	1	**7**
1.0, 2.0, 5.0	IMM	G. Y. Demirel	3	1	1	**5**
9.0	BS	Ç. Altunok	4	1	1	**6**
1.0, 2.0, 5.0	PP	M. Kaçar	3	1	1	**5**
2.0	MG	A.Ç. Kuşkucu	3	0	0	**3**
6.2	EM	S. Sarıkaya P. Tura	4	1	1	**6**
6.5	RAD	N. Taşdelen	1	0	0	**1**
		TOTAL	**90**	**22**	**22**	**134**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER / INSTRUCTOR**	**NUMBER of QUESTIONS (EMQ)**			
			CE	**FE**	**IE**	**Total**
1.0.-6.0	RHE	M. Bıçakçıgil Kalaycı	2	-	-	2
1.0-6.10	ORT	O. Kocadal	2	-	-	2
1.0-6.0	PTR	Ö. Ortancıl	1			1
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

pts: Points

****21** out of 200 FE and ICE MCQs will be from Committee VI (Each question is of worth **0.5** pts).

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK I / 31 May – 4 Jun 2021

	Monday 31-May-2021	Tuesday 1-Jun-2021	Wednesday 2-Jun-2021	Thursday 3-Jun-2021	Friday 4-Jun-2021
09.00- 09.50	**Lecture** Introduction to Musculoskeletal System F. Altıntaş	**Lecture** Degenerative Joint Disease F. Özkan	**Lecture** Osteoporosis and Osteoarthritis Treatment, Rehabilitation Ö. Ortancıl	**ICP-CSL** (Physical Examination of the Musculoskeletal System) H. T. Çift / O. Kocadal / G. Meriç	**Lecture** Public Health and Physical Activity I R. E. Sezer
10.00- 10.50	**Lecture** Degenerative Osteoarthrosis F. Altıntaş	**Lecture** Tumors of Soft Tissues I F. Özkan	**Lecture** Soft Tissue Pain Ö. Ortancıl	**Group A ICP** / **Group B Small Group Study** SRPC / **Group C IL** / **Group D IL**	**Lecture** Public Health and Physical Activity II R. E. Sezer
11.00- 11.50	**Lecture** Pathophysiology of Musculoskeletal System Disorders I M. Kaçar	**Lecture** Tumors of Soft Tissues II F. Özkan	**Lecture** Bone and Joint Infections Pathology Lecturer		**Lecture** Vasculitis I F. Özkan
12.00- 12.50	**Lecture** Pathophysiology of Musculoskeletal System Disorders II M. Kaçar	**Lecture** Frostbite / Burns P. Tura	**Lecture** Myopathies Pathology Lecturer	**Independent learning**	**Lecture** Vasculitis II F. Özkan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Congenital & Metabolic Diseases of Bone I Pathology Lecturer	**Lecture** Spondylarthropaties M. Bıçakçıgil Kalaycı	**Lecture** Foot Deformities B. Ç. Aksu	**Independent Learning**	**ELECTIVE WEEK XIV** / **Independent Learning**
15.00- 15.50	**Lecture** Congenital & Metabolic Diseases of Bone II Pathology Lecturer	**Lecture** Inflammatory Polyarthritis & Rheumatoid Arthritis M. Bıçakçıgil Kalaycı	**Lecture** Principles of Fracture Healing B. Ç. Aksu		
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Lecture** Initial Approach to Trauma Patient S. Sarıkaya		**Independent Learning** / **ELECTIVE WEEK XIV**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**		

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK II / 7-11 June 2021

	Monday 7-Jun-2021	Tuesday 8-Jun-2021	Wednesday 9-Jun-2021	Thursday 10-Jun-2021	Friday 11-Jun-2021
09.00- 09.50	**Lecture** Imaging of Musculoskeletal System N. Taşdelen	**ICP-CSL** **(**Suturing Technique) Dr. Süleyman Orman / Dr. Sermet Karagül	**Lecture** Osteomyelitis O. Kocadal	**ICP-CSL** **(**Physical Examination of the Musculoskeletal System) H. T. Çift / O. Kocadal / G. Meriç	**Lecture** Lower Extremity Trauma G. Meriç
10.00- 10.50	**Lecture** Miscellanous Rheumatological Disorders I M. Bıçakçıgil Kalaycı	**Group A** Small Group Study SRPC / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Septic Artritis O. Kocadal	**Group A** Small Group Study SRPC / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Traumatic Dislocations G. Meriç
11.00- 11.50	**Lecture** Miscellanous Rheumatological Disorders II M. Bıçakçıgil Kalaycı		**Lecture** Development Dysplasia of the Hip O. Kocadal		**Lecture** Spinal Trauma G. Meriç
12.00- 12.50	**Lecture** Miscellanous Rheumatological Disorders III M. Bıçakçıgil Kalaycı	**Independent Learning**	**Lecture** Upper Extremity Trauma O. Kocadal	**Independent Learning**	**Lecture** Skeletal Dysplasias A. Ç. Kuşkucu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Neck, Shoulder and Wrist Pain Ö. Ortancıl	**ICP-CSL** **(**Suturing Technique) Dr. Burak Çağrı Aksu / Dr. Utku Göktuğ	**ICP-CSL** (Physical Examination of the Musculoskeletal System) H. T. Çift / O. Kocadal / G. Meriç	**ICP-CSL** (Physical Examination of the Musculoskeletal System) H. T. Çift / O. Kocadal / G. Meriç	**Independent Learning**
15.00- 15.50	**Lecture** Low Back, Hip and Ankle Pain Ö. Ortancıl	**Group A IL** / **Group B IL** / **Group C** Small Group Study SRPC / **Group D ICP**	**Group A IL** / **Group B IL** / **Group C** Small Group Study SRPC / **Group D ICP**	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D** Small Group Study SRPC	
16.00- 16.50	**Lecture** Epidemiology, Prevention and Control of Occupational Diseases and Injuries I H.A. Taşyıkan				
17.00-17.50	**Lecture** Epidemiology, Prevention and Control of Occupational Diseases and Injuries II H.A. Taşyıkan	**Independent Learning**	**Independent Learning**	**Independent Learning**	

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK III / 14-18 Jun 2021

<table>
<tr><th></th><th>Monday
14-Jun-2021</th><th>Tuesday
15-Jun-2021</th><th>Wednesday
16-Jun-2021</th><th>Thursday
17-Jun-2021</th><th>Friday
18-Jun-2021</th></tr>
<tr><td>09.00- 09.50</td><td colspan="4">ICP-CSL
(Suturing Technique)
Dr. Murat Kuru / Dr. Mirkhakig Javadov</td><td rowspan="3">Independent Learning</td><td>Lecture
Connective Tissue Disorders I
M. Bıçakçıgil Kalaycı</td><td>Lecture
Spinal Deformities
H. T. Çift</td><td>Lecture
Management of the Trauma Patient
T. Özler</td></tr>
<tr><td>10.00- 10.50</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group C ICP</td><td rowspan="2">Group D Small Group Study SRPC</td><td>Lecture
Connective Tissue Disorders II
M. Bıçakçıgil Kalaycı</td><td>Lecture
Osteoporosis
H. T. Çift</td><td>Lecture
Complications of Fractures
G. Meriç</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Nonsteroidal Antiinflammatory Drugs I
E. Genç</td><td>Lecture
Benign Tumors of Bone
H. T. Çift</td><td>Lecture
Some Common Problems in Medical Research
Ç. Altunok</td></tr>
<tr><td>12.00- 12.50</td><td colspan="4">Independent Learning</td><td>Lecture
Nonsteroidal Antiinflammatory Drugs II
E. Genç</td><td>Lecture
Malignant Tumors of Bone
H. T. Çift</td><td>Lecture
Power Analysis and Sample Size Calculation I
Ç. Altunok</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="6">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td colspan="4">ICP-CSL
(Suturing Technique)
Dr. Fırat Demircan / Dr. Utku Göktuğ</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="2">Group A ICP</td><td rowspan="2">Group B SRPC</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td><td colspan="4">Independent Learning</td></tr>
</table>

Elective Courses Make-up Exams June 14-18, 2021

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK IV / 21-25 June 2021

	Monday 21-Jun-2021	Tuesday 22-Jun-2021	Wednesday 23-Jun-2021	Thursday 24-Jun-2021	Friday 25-Jun-2021
09.00- 09.50	**Lecture** Disease Modifying Antirheumatic Drugs Pharmacology Lecturer	**Lecture** Autopsy I A. Sav	**Lecture** Vasculitis I M. Bıçakçıgil Kalaycı	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Pharmacology Case Studies Pharmacology Lecturer	**Lecture** Autopsy II A. Sav	**Lecture** Vasculitis II M. Bıçakçıgil Kalaycı		
11.00- 11.50	**Lecture** Immune Mechanisms of Musculoskeletal Disorders G. Yanıkkaya Demirel	**Lecture** Power Analysis and Sample Size Calculation II Ç. Altunok	**Lecture** Management of Soft Tissue Disorders T. Özler		
12.00- 12.50	**Lecture** Immune Mechanisms of Musculoskeletal Disorders G. Yanıkkaya Demirel	**Lecture** Muscular Dystrophies A. Ç.Kuşkucu	**Lecture** Fractures of Children T. Özler		
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Skeletal Muscle Relaxants E. Genç	**Lecture** Bone Tumors I Pathology Lecturer	**Multidisciplinary Case Discussion Panel**	**Independent Learning**	**Independent Learning**
15.00- 15.50	**Independent Learning**	**Lecture** Bone Tumors II Pathology Lecturer	**Multidisciplinary Case Discussion Panel**		
16.00- 16.50		**Pathology Laboratory** (Musculoskeletal System) A.Sav / F. Özkan — Group A / Group B IL	**Independent Learning**		
17.00-17.50		Group A IL / Group B	**Independent Learning**		

Elective Courses Final Exams June 21-28, 2021

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK V / 28 June – 2 July 2021

	Monday 28-Jun-2021	Tuesday 29-Jun-2021	Wednesday 30-Jun-2021	Thursday 1-Jun-2021	Friday 2-Jun-2021
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					
11.00- 11.50					COMMITTEE EXAM
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				Program Evaluation Session Committee VI Coordination Committee Members
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

STUDENT COUNSELING

Student counseling is a structured development process established between the student and the consultant that aims to maximize student success by focusing the student to her/his target. Although the major component of this relationship is the student, the faculties also take part by bringing the requirements of this interaction to their systems. The targeted outcomes of the consultant-student interaction are success in the exams, success in the program, and preparation for the professional life. The aim of counseling is to help students to solve their problems, to give professional guidance, to provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about the University and Faculty, to follow their success and failure and to help them select courses.
The consultants selected among Basic Medical Sciences instructors for the first three years transfer the students to Clinical Sciences instructors for the following three years.

The topics that will be addressed by the consultants are as follows:

a. Inform students about the university, faculty and surrounding facilities
b. Inform students about the courses and help them select courses
c. Inform students about the education and assessment regulations
d. Follow students attendance to lectures and success
e. In case of failure, investigate the causes and cooperate with the students to overcome them
f. Help students in career planning
g. Contribute to students adapting the habit of lifelong learning
h. Guide students to counseling services of the university
i. Set a role model as long as the professional susceptibility, professional guidance, intellectual responsibility, interaction with peers, ethics, professional values are concerned
j. Contribute to cultivation of professional and intellectual development in a rapidly changing world
k. Inform the coordinator when there are unsolved problems of the students

Consultant-student relationship is a dynamic and mutual process carried out within the campus and the hospital. It is recommended that the consultant and the student meet at least twice during a semester.

The expectations from the student are as follows:

a) Contribute to improvement of satisfaction level in the problem areas
b) Report the social and economic conditions that require consultant's help
c) Specify expectations from the education and the department from which this training is taken
d) Give feedback on the counseling services regarding their satisfaction level

Student counsellors will be appointed after finalization of the class list and will be announced to the students.
After the announcement of the counsellors on the information board, each student is expected to contact his/her counsellor until the end of the current committee.

The student counseling lists are announced through the Google Classroom pages of the respective phase.

CONTACT

Faculty Secretary :
Tel: +90 216 578 00 00 (3005)

Dean Secretary:
Tel: +90 216 578 05 05 – 06
Fax: +90 216 578 05 75

Student Affairs :
Tel: +90 216 578 06 86

Documents Affairs:
Tel: +90 216 578 05 93

Phase 3 Coordinator/ Co-coordinators:

Hale Arık Taşyıkan, MD, Assist. Prof. (Coordinator), 0216 578 00 00 (6300) / hale.arik@yeditepe.edu.tr

Hasan Aydın, MD, Prof. (Co-coordinator), 0216 578 00 00 (4095) / haydin@yeditepe.edu.tr

Erdem Söztutar, Assist. Prof (Co-coordinator), 0216 578 00 / erdem.soztutar@yeditepe.edu.tr

Emine Nur Özdamar, MD, Assist. Prof. (Co-coordinator), 0216 578 00 / nur.ozdamar@yeditepe.edu.tr

Özlem Tanrıöver, MD, Prof. (ICP Coordinator), 216 578 00 00 (3742) / otanriover@yeditepe.edu.tr

A. Arzu Akalın, MD, Assist. Prof. (ICP Co-coordinator & Elective Courses Coordinator), 216 578 00 00 (1525) / arzu.akalin@yeditepe.edu.tr

Seda Güleç, PhD. Assoc. Prof. (Elective Courses Co-coordinator) 216 578 00 00 / seda.gulec@yeditepe.edu.tr

Address:

Yeditepe University Faculty of Medicine
İnönü Mah. Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

Web : www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
e-mail: tipfakdek@yeditepe.edu.tr

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE

İnönü Mah. Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

+ 90 216 578 00 00

www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
tipfakdek@yeditepe.edu.tr